United Kingdom Refractory Asthma Stratification Programme (RASP-UK)
Lead Research Organisation:
Queen's University Belfast
Department Name: Sch of Medicine, Dentistry & Biomed Sci
Abstract
Severe refractory asthma affects approximately 2% of the UK population, and has a total healthcare cost that is greater than that for all of the 10 - 15% of the population with mild/moderate asthma. International asthma guidelines advise the 'step-wise' increase of inhaled and oral corticosteroid treatment. However, for severe refractory asthma, the response to corticosteroids is often poor, and doctors often escalate to high dose inhaled or oral corticosteroids. Recent data suggests that this "one size fits all" approach to asthma treatment is poorly targeted. Our industry partners are developing new drugs for severe asthma, which will require a targeted approach in patients to identify who will respond.
We propose a two level approach:
(i) In some patients with severe asthma, a key clinical problem is non-adherence with corticosteroid therapy (non-adherence is where patients, intentionally or non-intentionally, do not take their prescribed treatment). This is common and is poorly recognised by physicians. It can result in patients being inappropriately labelled as having 'corticosteroid resistant' disease, and may cause patients to be escalated to more complex and expensive therapies, when they could be controlled on inhaled corticosteroid treatment. Assessing adherence objectively is a pre-requisite to optimising corticosteroid therapy. This programme will assess adherence using remote monitoring technologies and non-adherent patients will be assisted and managed within their clinical service.
(ii) Some severe asthma patients have inappropriate increases in corticosteroids in the absence of corticosteroid responsive inflammation, and this can cause significant harm due to treatment side-effects, without any treatment benefit. Our programme will validate a new way to optimise corticosteroid therapy using simple blood (blood eosinophil count, serum periostin level) and breath (exhaled nitric oxide) tests of corticosteroid response across the major United Kingdom Clinical Centres for Severe Asthma. We know that patients with low measures of these biomarkers have a low chance of having an asthma attack and we can safely reduce and optimise their corticosteroid treatment dose. This process of corticosteroid optimisation will identify two populations of severe asthma patients, with different patterns of lung inflammation, one with corticosteroid responsive disease with high eosinophils (these are inflammatory cells recruited to the lungs in asthma) which we call "T2-High"severe asthma and the other with corticosteroid unresponsive disease or "T2-Low" severe asthma. The T2-High group will be available for clinical trials of novel treatments which have already been developed by the Pharmaceutical Industry. We currently understand much less about the T2-Low group, and they will be studied intensively with measures of lung function and other tests including airway sampling using bronchoscopy (a telescope test in the lungs to get airway samples) . We will also follow them up for 12 months to see if they remain stable on their optimised corticosteroid dose and if the pattern of inflammation in the lungs changes over time. This strategy will help us identify new drug targets for this group, and these patients will then be able to enter trials of these novel treatments.
This programme is the first to take this type of stratification approach in severe refractory asthma, specifically to assess objectively adherence to current treatment, and then to test a way to optimise corticosteroid therapy. It will provide a world-leading step change in the care of patients with severe asthma. It will also enable a clinical trials programme to be expanded within the UK Severe Asthma Clinical Centres to allow the safe and targeted testing of new treatments.
We propose a two level approach:
(i) In some patients with severe asthma, a key clinical problem is non-adherence with corticosteroid therapy (non-adherence is where patients, intentionally or non-intentionally, do not take their prescribed treatment). This is common and is poorly recognised by physicians. It can result in patients being inappropriately labelled as having 'corticosteroid resistant' disease, and may cause patients to be escalated to more complex and expensive therapies, when they could be controlled on inhaled corticosteroid treatment. Assessing adherence objectively is a pre-requisite to optimising corticosteroid therapy. This programme will assess adherence using remote monitoring technologies and non-adherent patients will be assisted and managed within their clinical service.
(ii) Some severe asthma patients have inappropriate increases in corticosteroids in the absence of corticosteroid responsive inflammation, and this can cause significant harm due to treatment side-effects, without any treatment benefit. Our programme will validate a new way to optimise corticosteroid therapy using simple blood (blood eosinophil count, serum periostin level) and breath (exhaled nitric oxide) tests of corticosteroid response across the major United Kingdom Clinical Centres for Severe Asthma. We know that patients with low measures of these biomarkers have a low chance of having an asthma attack and we can safely reduce and optimise their corticosteroid treatment dose. This process of corticosteroid optimisation will identify two populations of severe asthma patients, with different patterns of lung inflammation, one with corticosteroid responsive disease with high eosinophils (these are inflammatory cells recruited to the lungs in asthma) which we call "T2-High"severe asthma and the other with corticosteroid unresponsive disease or "T2-Low" severe asthma. The T2-High group will be available for clinical trials of novel treatments which have already been developed by the Pharmaceutical Industry. We currently understand much less about the T2-Low group, and they will be studied intensively with measures of lung function and other tests including airway sampling using bronchoscopy (a telescope test in the lungs to get airway samples) . We will also follow them up for 12 months to see if they remain stable on their optimised corticosteroid dose and if the pattern of inflammation in the lungs changes over time. This strategy will help us identify new drug targets for this group, and these patients will then be able to enter trials of these novel treatments.
This programme is the first to take this type of stratification approach in severe refractory asthma, specifically to assess objectively adherence to current treatment, and then to test a way to optimise corticosteroid therapy. It will provide a world-leading step change in the care of patients with severe asthma. It will also enable a clinical trials programme to be expanded within the UK Severe Asthma Clinical Centres to allow the safe and targeted testing of new treatments.
Technical Summary
This programme will test a novel stratification strategy in severe asthma to improve clinical management and accelerate development of new therapies. There are 4 components:
1. Stratification by adherence to regular corticosteroid (CS) treatment. Objective identification of adherence to inhaled CS to (a) precisely identify truly CS unresponsive asthma phenotypes where new drugs are needed and (b) avoid inappropriate use of new complex therapies in patients who could be effectively controlled on inhaled CS.
2. Biomarker-based titration of CS therapy. In the absence of CS responsive inflammation, clinical response to CS is minimal and inappropriate CS escalation causes significant morbidity. In a 1-year, multi-centre randomised clinical trial, comparing biomarker titrated CS therapy to standard care, we will examine if individualised titration of CS dose using validated biomarkers (exhaled nitric oxide, blood eosinophil count and serum periostin) improves asthma outcome. This will also address another key question, specifically what proportion of patients with severe asthma develop typical eosinophilic airways inflammation associated with Type 2 cytokines (T2) on progressive CS withdrawal.
3. Identification of new therapeutic targets. Prior genetic/mechanistic studies of asthma have not stratified on inflammatory phenotype; thus, understanding of the pathophysiological mechanisms in which T2 inflammation is absent is poor. We will undertake deep-phenotyping of the stratified cohorts to identify important structure/function relationships.
4. Clinical trials programme for new T2 and non-T2 therapies. Stratification by inflammatory phenotype is central to novel target-specific therapies and biomarker-driven therapeutic options now exist for severe asthma. We will use our established clinical infrastructure to engage with pharmaceutical companies to facilitate access to stratified severe asthma patient populations for Phase 2 proof of concept studies.
1. Stratification by adherence to regular corticosteroid (CS) treatment. Objective identification of adherence to inhaled CS to (a) precisely identify truly CS unresponsive asthma phenotypes where new drugs are needed and (b) avoid inappropriate use of new complex therapies in patients who could be effectively controlled on inhaled CS.
2. Biomarker-based titration of CS therapy. In the absence of CS responsive inflammation, clinical response to CS is minimal and inappropriate CS escalation causes significant morbidity. In a 1-year, multi-centre randomised clinical trial, comparing biomarker titrated CS therapy to standard care, we will examine if individualised titration of CS dose using validated biomarkers (exhaled nitric oxide, blood eosinophil count and serum periostin) improves asthma outcome. This will also address another key question, specifically what proportion of patients with severe asthma develop typical eosinophilic airways inflammation associated with Type 2 cytokines (T2) on progressive CS withdrawal.
3. Identification of new therapeutic targets. Prior genetic/mechanistic studies of asthma have not stratified on inflammatory phenotype; thus, understanding of the pathophysiological mechanisms in which T2 inflammation is absent is poor. We will undertake deep-phenotyping of the stratified cohorts to identify important structure/function relationships.
4. Clinical trials programme for new T2 and non-T2 therapies. Stratification by inflammatory phenotype is central to novel target-specific therapies and biomarker-driven therapeutic options now exist for severe asthma. We will use our established clinical infrastructure to engage with pharmaceutical companies to facilitate access to stratified severe asthma patient populations for Phase 2 proof of concept studies.
Planned Impact
Patients - will benefit through the development of a logical approach to treatment, based on an innovative and objective biomarker-driven algorithm. Currently, treatment is based on a "blunderbuss" approach using high dose corticosteroids, without definite clinical effectiveness in any individual, but with predictable long term side-effects. This is unacceptable for the estimated 50% of severe asthma patients who do not respond to escalation of corticosteroid therapy. This programme will firstly assess adherence using simple home-based remote testing, and then secondly validate a simple clinical biomarker based algorithm, to optimise an individual's corticosteroid dose. This will improve patient outcomes, and many patients will have their corticosteroid burden reduced, with fewer long-term corticosteroid side-effects. Optimised patients with persistent severe asthma will then be able to take part in trials of novel targeted treatments. International treatment guidelines will adopt this strategy for severe asthma and Consortium members will disseminate data to support evidence-based management of severe asthma worldwide. Asthma UK is a Consortium partner, represents the patient's interests, and will lead on the communication of the outcomes to patients.
Clinicians - will be able to adopt outputs from this programme with an immediate and direct impact on clinical care. They will be able to identify poor adherence and engage in a transparent discussion with patients. The composite biomarker strategy (exhaled nitric oxide, blood eosinophil count and serum periostin) will be easily transferable into the clinic and will deliver more effective targeting of corticosteroids. These tests are simple, rapid and reproducible and will enable 'near patient' testing to make treatment decisions in severe asthma. Clinicians will avoid inappropriate use of novel biologics, and will be able to target them more appropriately.
Academics - will benefit from improved understanding of the mechanisms underlying different asthma endotypes. The POC studies clarifying the role for novel therapies directed against NOX4 and other novel molecules will be central to a stratified approach in severe asthma. We recognise that even with the new therapies in development, we are unlikely to have all the tools to treat all aspects of severe asthma and our stratification programme will facilitate the identification of new targets for the 'non-corticosteroid responsive' aspects of asthma, which will also in the longer term, provide substantial patient benefit.
Industry - Our industry partners have helped shape the programme, and strongly endorse the Consortium's stratification approach. Non-adherent patients often become adherent with corticosteroid therapy when closely supervised in clinical trials and as a result, trials are underpowered. Defining a 'gold standard' assessment of adherence will reduce trial size and/or increase power and save costs. Diagnostic companies in our Consortium will have the utility of the novel strategy assessed independently. Therapeutics companies will have access to cohorts of precisely phenotyped patients for the identification of novel targets, and for the testing of targeted new treatments. In the long term, it will provide a world-leading cohesive and stable clinical infrastructure, to design and deliver stratified proof of concept clinical trials, and thus speed up the drug development process.
Healthcare providers and policy makers - will have additional information relating to responsiveness and non-adherence to corticosteroid treatment and a strong evidence base for introducing new and expensive treatments for severe asthma. Targeting new treatments to responder populations will deliver economic benefit by avoiding inappropriate use of expensive novel therapies in patients who are either non-adherent with simpler less expensive treatments, or whose inflammatory phenotype is unresponsive to a new medication.
Clinicians - will be able to adopt outputs from this programme with an immediate and direct impact on clinical care. They will be able to identify poor adherence and engage in a transparent discussion with patients. The composite biomarker strategy (exhaled nitric oxide, blood eosinophil count and serum periostin) will be easily transferable into the clinic and will deliver more effective targeting of corticosteroids. These tests are simple, rapid and reproducible and will enable 'near patient' testing to make treatment decisions in severe asthma. Clinicians will avoid inappropriate use of novel biologics, and will be able to target them more appropriately.
Academics - will benefit from improved understanding of the mechanisms underlying different asthma endotypes. The POC studies clarifying the role for novel therapies directed against NOX4 and other novel molecules will be central to a stratified approach in severe asthma. We recognise that even with the new therapies in development, we are unlikely to have all the tools to treat all aspects of severe asthma and our stratification programme will facilitate the identification of new targets for the 'non-corticosteroid responsive' aspects of asthma, which will also in the longer term, provide substantial patient benefit.
Industry - Our industry partners have helped shape the programme, and strongly endorse the Consortium's stratification approach. Non-adherent patients often become adherent with corticosteroid therapy when closely supervised in clinical trials and as a result, trials are underpowered. Defining a 'gold standard' assessment of adherence will reduce trial size and/or increase power and save costs. Diagnostic companies in our Consortium will have the utility of the novel strategy assessed independently. Therapeutics companies will have access to cohorts of precisely phenotyped patients for the identification of novel targets, and for the testing of targeted new treatments. In the long term, it will provide a world-leading cohesive and stable clinical infrastructure, to design and deliver stratified proof of concept clinical trials, and thus speed up the drug development process.
Healthcare providers and policy makers - will have additional information relating to responsiveness and non-adherence to corticosteroid treatment and a strong evidence base for introducing new and expensive treatments for severe asthma. Targeting new treatments to responder populations will deliver economic benefit by avoiding inappropriate use of expensive novel therapies in patients who are either non-adherent with simpler less expensive treatments, or whose inflammatory phenotype is unresponsive to a new medication.
Organisations
- Queen's University Belfast (Lead Research Organisation)
- Karolinska Institute (Collaboration)
- Owlstone Ltd (Collaboration)
- Vitalograph (Collaboration)
- Birmingham Heartlands Hospital (Collaboration)
- Amsterdam Medical Center (Collaboration)
- EURICE (Collaboration)
- Royal Brompton Hospital (Collaboration)
- Medical Research Council (MRC) (Collaboration)
- South West Acute Hospital (Collaboration)
- UNIVERSITY OF SOUTHAMPTON (Collaboration)
- Heart of England NHS Foundation Trust (Collaboration)
- European Respiratory Society (ERS) (Collaboration)
- NHS Greater Glasgow and Clyde (NHSGGC) (Collaboration)
- University of Lodz (Collaboration)
- Cavan General Hospital (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- European Lung Foundation (Collaboration)
- Belfast City Hospital (Collaboration)
- Imperial College Healthcare NHS Trust (Collaboration)
- Janssen Research & Development (Collaboration)
- UNIVERSITY OF GLASGOW (Collaboration)
- PORTSMOUTH HOSPITALS NHS TRUST (Collaboration)
- KING'S COLLEGE LONDON (Collaboration)
- Austrian Society of Pneumology (Collaboration)
- Philipp University of Marburg (Collaboration)
- ROYAL BROMPTON & HAREFIELD NHS FOUNDATION TRUST (Collaboration)
- Amgen Inc (Collaboration)
- Niche.com, Inc. (Collaboration)
- Asthma + Lung UK (Collaboration)
- Daisy Hill Hospital (Collaboration)
- Our Lady of Lourdes Hospital (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- University of Manchester (Collaboration)
- University College London (Collaboration)
- UNIVERSITY OF LEICESTER (Collaboration)
- Meyer Children's Hospital (Collaboration)
- UNIVERSITY OF NOTTINGHAM (Collaboration)
- BARTS HEALTH NHS TRUST (Collaboration)
- Royal College of Surgeons in Ireland (Collaboration)
- Genentech, Inc (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- Letterkenny General Hospital (Collaboration)
- AstraZeneca (United Kingdom) (Collaboration)
- AlveoliX AG (Collaboration)
- The French Respiratory Society (Collaboration)
- Aerocrine (Collaboration)
- NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST (Collaboration)
- Boehringer Ingelheim (Collaboration)
- University Medical Center Gronigen (Collaboration)
- Bispebjerg Hospital (Collaboration)
- Center for Biomedical Research Network (Collaboration)
- Roche (United States) (Project Partner)
- Amgen (United States) (Project Partner)
- Aerocrine (Sweden) (Project Partner)
- Vitalograph (Ireland) (Project Partner)
- AstraZeneca (United States) (Project Partner)
- Janssen (United States) (Project Partner)
Publications
Adcock I
(2022)
The Use of Inhaled Corticosteroids for Patients with COPD Who Continue to Smoke Cigarettes: An Evaluation of Current Practice
in The American Journal of Medicine
Agache I
(2023)
Multidimensional endotyping using nasal proteomics predicts molecular phenotypes in the asthmatic airways.
in The Journal of allergy and clinical immunology
Amani S
(2021)
Angiogenic effects of cell therapy within a biomaterial scaffold in a rat hind limb ischemia model
in Scientific Reports
Badi YE
(2023)
IL1RAP expression and the enrichment of IL-33 activation signatures in severe neutrophilic asthma.
in Allergy
Barry LE
(2023)
Cost-Effectiveness of Fractional Exhaled Nitric Oxide Suppression Testing as an Adherence Screening Tool Among Patients With Difficult-to-Control Asthma.
in The journal of allergy and clinical immunology. In practice
Bender BG
(2019)
Sorting Out Nonadherence and Airway Inflammation in Treatment Escalation for Severe Asthma.
in American journal of respiratory and critical care medicine
Boddy CE
(2021)
Clinical Outcomes in People with Difficult-to-Control Asthma Using Electronic Monitoring to Support Medication Adherence.
in The journal of allergy and clinical immunology. In practice
Busby J
(2020)
Using prednisolone and cortisol assays to assess adherence in oral corticosteroid dependant asthma: An analysis of test-retest repeatability.
in Pulmonary pharmacology & therapeutics
Busby J
(2022)
Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma.
in The European respiratory journal
| Description | Academy of Medical Sciences Summary Report March 2017. The Academy of Medical Sciences hosted a roundtable meeting to bring together key stakeholders to deliver stratified approaches to severe asthma in the NHS. Much of the proposed stratification process is aligned with the stratification pathway in RASP UK and RASP-UK will continue to provide important information in this patient group. Clinical Pathway prepared by Professor LG Heaney, Professor R Djukanovic and Professor ID Pavord. |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| URL | https://acmedsci.ac.uk/file-download/20348674 |
| Description | GINA International Asthma Guidelines. |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in other policy documents |
| URL | https://ginasthma.org/gina-reports/ |
| Description | BenRex |
| Amount | £2,572,762 (GBP) |
| Organisation | AstraZeneca |
| Sector | Private |
| Country | United Kingdom |
| Start | 06/2019 |
| End | 06/2023 |
| Description | Boehringer Ingelheim Consortium Partnership |
| Amount | £450,000 (GBP) |
| Organisation | Boehringer Ingelheim |
| Sector | Private |
| Country | Germany |
| Start | 03/2017 |
| End | 10/2020 |
| Description | European Commission H2020 |
| Amount | € 4,030,000 (EUR) |
| Funding ID | 831434 |
| Organisation | European Commission H2020 |
| Sector | Public |
| Country | Belgium |
| Start | 06/2019 |
| End | 06/2026 |
| Description | GSK Consortium Partnership |
| Amount | £450,000 (GBP) |
| Organisation | GlaxoSmithKline (GSK) |
| Sector | Private |
| Country | Global |
| Start | 12/2016 |
| End | 10/2020 |
| Description | GSK ISS |
| Amount | £864,795 (GBP) |
| Organisation | GlaxoSmithKline (GSK) |
| Sector | Private |
| Country | Global |
| Start | 11/2020 |
| End | 06/2022 |
| Description | Leveraged Clinical Fellow |
| Amount | £160,000 (GBP) |
| Organisation | Queen's University Belfast |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 08/2016 |
| Description | Leveraged PhD Studentship |
| Amount | £48,000 (GBP) |
| Organisation | Queen's University Belfast |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 09/2019 |
| Description | PhD Studentship |
| Amount | € 108,000 (EUR) |
| Organisation | Royal College of Surgeons in Ireland |
| Sector | Academic/University |
| Country | Ireland |
| Start | 09/2015 |
| End | 08/2018 |
| Title | RASP UK Data management Platform |
| Description | The clinical and omics data sets of RASP-UK have been successfully uploaded to the tranSMART platform, which platform enables real-time analyses. It has been aligned with the UBIOPRED and SOMOSA datasets and ensures accessibility, sustainability and transparency of data which is essential for future respiratory projects within the EU and the UK. Requests for accessing the RASP-UK data management platform will be managed by the RASP-UK Legacy Committee. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2022 |
| Provided To Others? | Yes |
| Impact | The first request for access to data and samples has been approved using data and bronchial biopsy samples in a project entitled ' High resolution spatial analyses of pathology in airway tissues in the MRC RASP-UK severe asthma cohort'. The study will apply novel, high-resolution, spatial transcriptomics, proteomics, lipidomics and epigenomics to bronchial biopsy samples from are unique cohort of highly-phenotyped treatment-optimised people with severe asthma. For the first time this will enable elucidation of underlying mechanisms of airway inflammation and tissue remodelling in severe asthma that cannot be obtained from bulk tissue analyses. Thus it will be possible to study the role of alarmins from airway epithelial cells and of type-2 cytokines, chemokines and eicosanoid mediators from specific inflammatory cells within the airway mucosa in ICS resistance; and identify differences in the airway smooth muscle and epithelial transcriptome, proteome, and epigenome in T2-biomarker high and low asthma that support ongoing airway smooth muscle dysfunction driving bronchoconstriction and airway hyperresponsiveness, and the goblet cell hyperplasia that drives excess mucus secretion, irrespective of the cytokine environment. This project is being undertaken through a collaboration involving the Universities of Leicester, Oxford and Nottingham, and is the subject of a current application to the MRC PSMB |
| URL | https://rasp.dsi.ic.ac.uk/transmart/login/auth |
| Description | ADON ERS 3TR Collaboration |
| Organisation | AlveoliX AG |
| Country | Switzerland |
| Sector | Private |
| PI Contribution | Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma. |
| Collaborator Contribution | The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4. |
| Impact | None as yet |
| Start Year | 2019 |
| Description | ADON ERS 3TR Collaboration |
| Organisation | Amsterdam Medical Center |
| Country | Netherlands |
| Sector | Hospitals |
| PI Contribution | Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma. |
| Collaborator Contribution | The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4. |
| Impact | None as yet |
| Start Year | 2019 |
| Description | ADON ERS 3TR Collaboration |
| Organisation | Austrian Society of Pneumology |
| Country | Austria |
| Sector | Learned Society |
| PI Contribution | Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma. |
| Collaborator Contribution | The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4. |
| Impact | None as yet |
| Start Year | 2019 |
| Description | ADON ERS 3TR Collaboration |
| Organisation | Bispebjerg Hospital |
| Country | Denmark |
| Sector | Hospitals |
| PI Contribution | Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma. |
| Collaborator Contribution | The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4. |
| Impact | None as yet |
| Start Year | 2019 |
| Description | ADON ERS 3TR Collaboration |
| Organisation | Center for Biomedical Research Network |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma. |
| Collaborator Contribution | The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4. |
| Impact | None as yet |
| Start Year | 2019 |
| Description | ADON ERS 3TR Collaboration |
| Organisation | EURICE |
| Country | Germany |
| Sector | Public |
| PI Contribution | Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma. |
| Collaborator Contribution | The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4. |
| Impact | None as yet |
| Start Year | 2019 |
| Description | ADON ERS 3TR Collaboration |
| Organisation | European Lung Foundation |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma. |
| Collaborator Contribution | The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4. |
| Impact | None as yet |
| Start Year | 2019 |
| Description | ADON ERS 3TR Collaboration |
| Organisation | European Respiratory Society (ERS) |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma. |
| Collaborator Contribution | The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4. |
| Impact | None as yet |
| Start Year | 2019 |
| Description | ADON ERS 3TR Collaboration |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma. |
| Collaborator Contribution | The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4. |
| Impact | None as yet |
| Start Year | 2019 |
| Description | ADON ERS 3TR Collaboration |
| Organisation | Karolinska Institute |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma. |
| Collaborator Contribution | The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4. |
| Impact | None as yet |
| Start Year | 2019 |
| Description | ADON ERS 3TR Collaboration |
| Organisation | Meyer Children's Hospital |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma. |
| Collaborator Contribution | The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4. |
| Impact | None as yet |
| Start Year | 2019 |
| Description | ADON ERS 3TR Collaboration |
| Organisation | Owlstone Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma. |
| Collaborator Contribution | The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4. |
| Impact | None as yet |
| Start Year | 2019 |
| Description | ADON ERS 3TR Collaboration |
| Organisation | Philipp University of Marburg |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma. |
| Collaborator Contribution | The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4. |
| Impact | None as yet |
| Start Year | 2019 |
| Description | ADON ERS 3TR Collaboration |
| Organisation | The French Respiratory Society |
| Country | France |
| Sector | Charity/Non Profit |
| PI Contribution | Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma. |
| Collaborator Contribution | The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4. |
| Impact | None as yet |
| Start Year | 2019 |
| Description | ADON ERS 3TR Collaboration |
| Organisation | University Medical Center Gronigen |
| Department | Rheumatology and Clinical Immunology (UMCG-R) |
| Country | Netherlands |
| Sector | Hospitals |
| PI Contribution | Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma. |
| Collaborator Contribution | The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4. |
| Impact | None as yet |
| Start Year | 2019 |
| Description | ADON ERS 3TR Collaboration |
| Organisation | University of Leicester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma. |
| Collaborator Contribution | The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4. |
| Impact | None as yet |
| Start Year | 2019 |
| Description | ADON ERS 3TR Collaboration |
| Organisation | University of Lodz |
| Country | Poland |
| Sector | Academic/University |
| PI Contribution | Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma. |
| Collaborator Contribution | The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4. |
| Impact | None as yet |
| Start Year | 2019 |
| Description | ADON ERS 3TR Collaboration |
| Organisation | University of Southampton |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provision of data and samples for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform including data from studies in RASP-UK programme - MEX Trial (an observational trial being looking at exacerbation phenotypes and anti-IL- 5 in asthma, 2) BEN-REX (an exacerbation study an observational trial being looking at exacerbation phenotypes on anti-IL- 5R antagonost in asthma, 3) SOMOSA (an interventional study which is part of RASP UK, partners QUB and SOTON) which is examining biomarkers for response to anti-IgE in asthma. |
| Collaborator Contribution | The partnership will aim to 1. catalogue retrospective studies, determine the current and prospective observational and interventional trials to be aligned to 3TR and develop Pan-European pragmatic clinical trial platforms to support embedded experimental medicine studies; 2. use provided data and samples (to enable integrated multi-scale omics of host and exposome) for the identification of predictors of response, biomarkers, and new therapeutic targets via a harmonized bioresource and knowledge management platform; 3: redefine response and nonresponse by establishing the best practices for predictor and biomarker development through the incorporation of the patient perspective and regulatory input together with other disease areas; 4: determine the immune-mediated mechanisms of response or non-response to immunological targeted therapies in asthma and COPD with the data interpretation group integrated within and across the disease areas; 5: develop and access a platform of validation models and assays to further support and validate mechanisms, targets and biomarkers delineated from objectives 2 and 4. |
| Impact | None as yet |
| Start Year | 2019 |
| Description | Beyond Allergic TH2 Severe Asthma (BEAT EME) |
| Organisation | Asthma + Lung UK |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Expertise as coordinator of MRC-RASP program. |
| Collaborator Contribution | Universities of Leicester (Siddiqui-Coordinator, Brightling, Wardlaw) bring expertise in program management, bio sample tracking, phenotyping, clinical trials, sputum profiling, eosinophil biology, clinical microbiomics and have links to their molecular pathology node. University of Nottingham (Shaw, Harrison) have a track record in asthma clinical trials, coordinate the respiratory translational research collaboration. University of Southampton (Djukanovic, Skipp) bring expertise in severe asthma clinical trials, developing bio-stratification tools in trial (e.g. European IMI funded UBIOPRED consortium) and high throughput urinary proteomics. University of Oxford (Pavord) designed pivotal trials of Mepolizumab in severe asthma. University of Glasgow (Chaudhuri) brings expertise in asthma trials and coordinates the clinical trial work package in MRC-RASP. Imperial College (Chung) has expertise acquired via analysis of the UBIOPRED cohort. University of Manchester (Fowler),Barts Health Care Trust (Pfeffer), Royal Brompton Hospital (Menzies-Gow), Birmingham Heartlands Hospital (Mansur), Guys and St Thomas's Hospital (Jackson) and the Universities of Portsmouth (Chauhan), Swansea (Davies), Norwich (Wilson), all have expertise in clinical trial delivery. The MRC CTU at UCL (Parmar and Brown) are leaders in clinical trial methodology and Leicester CTU (Barber) have expertise as a registered CTU providing full trial support and co-ordination of clinical trials. Asthma UK (Walker) has developed a strategic road map for asthma innovation to drive EU funding in asthma (EARIP program). Val Hudson (patient) has expertise in asthma PPI. |
| Impact | None yet. |
| Start Year | 2019 |
| Description | Beyond Allergic TH2 Severe Asthma (BEAT EME) |
| Organisation | Barts Health NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Expertise as coordinator of MRC-RASP program. |
| Collaborator Contribution | Universities of Leicester (Siddiqui-Coordinator, Brightling, Wardlaw) bring expertise in program management, bio sample tracking, phenotyping, clinical trials, sputum profiling, eosinophil biology, clinical microbiomics and have links to their molecular pathology node. University of Nottingham (Shaw, Harrison) have a track record in asthma clinical trials, coordinate the respiratory translational research collaboration. University of Southampton (Djukanovic, Skipp) bring expertise in severe asthma clinical trials, developing bio-stratification tools in trial (e.g. European IMI funded UBIOPRED consortium) and high throughput urinary proteomics. University of Oxford (Pavord) designed pivotal trials of Mepolizumab in severe asthma. University of Glasgow (Chaudhuri) brings expertise in asthma trials and coordinates the clinical trial work package in MRC-RASP. Imperial College (Chung) has expertise acquired via analysis of the UBIOPRED cohort. University of Manchester (Fowler),Barts Health Care Trust (Pfeffer), Royal Brompton Hospital (Menzies-Gow), Birmingham Heartlands Hospital (Mansur), Guys and St Thomas's Hospital (Jackson) and the Universities of Portsmouth (Chauhan), Swansea (Davies), Norwich (Wilson), all have expertise in clinical trial delivery. The MRC CTU at UCL (Parmar and Brown) are leaders in clinical trial methodology and Leicester CTU (Barber) have expertise as a registered CTU providing full trial support and co-ordination of clinical trials. Asthma UK (Walker) has developed a strategic road map for asthma innovation to drive EU funding in asthma (EARIP program). Val Hudson (patient) has expertise in asthma PPI. |
| Impact | None yet. |
| Start Year | 2019 |
| Description | Beyond Allergic TH2 Severe Asthma (BEAT EME) |
| Organisation | Birmingham Heartlands Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Expertise as coordinator of MRC-RASP program. |
| Collaborator Contribution | Universities of Leicester (Siddiqui-Coordinator, Brightling, Wardlaw) bring expertise in program management, bio sample tracking, phenotyping, clinical trials, sputum profiling, eosinophil biology, clinical microbiomics and have links to their molecular pathology node. University of Nottingham (Shaw, Harrison) have a track record in asthma clinical trials, coordinate the respiratory translational research collaboration. University of Southampton (Djukanovic, Skipp) bring expertise in severe asthma clinical trials, developing bio-stratification tools in trial (e.g. European IMI funded UBIOPRED consortium) and high throughput urinary proteomics. University of Oxford (Pavord) designed pivotal trials of Mepolizumab in severe asthma. University of Glasgow (Chaudhuri) brings expertise in asthma trials and coordinates the clinical trial work package in MRC-RASP. Imperial College (Chung) has expertise acquired via analysis of the UBIOPRED cohort. University of Manchester (Fowler),Barts Health Care Trust (Pfeffer), Royal Brompton Hospital (Menzies-Gow), Birmingham Heartlands Hospital (Mansur), Guys and St Thomas's Hospital (Jackson) and the Universities of Portsmouth (Chauhan), Swansea (Davies), Norwich (Wilson), all have expertise in clinical trial delivery. The MRC CTU at UCL (Parmar and Brown) are leaders in clinical trial methodology and Leicester CTU (Barber) have expertise as a registered CTU providing full trial support and co-ordination of clinical trials. Asthma UK (Walker) has developed a strategic road map for asthma innovation to drive EU funding in asthma (EARIP program). Val Hudson (patient) has expertise in asthma PPI. |
| Impact | None yet. |
| Start Year | 2019 |
| Description | Beyond Allergic TH2 Severe Asthma (BEAT EME) |
| Organisation | Imperial College Healthcare NHS Trust |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Expertise as coordinator of MRC-RASP program. |
| Collaborator Contribution | Universities of Leicester (Siddiqui-Coordinator, Brightling, Wardlaw) bring expertise in program management, bio sample tracking, phenotyping, clinical trials, sputum profiling, eosinophil biology, clinical microbiomics and have links to their molecular pathology node. University of Nottingham (Shaw, Harrison) have a track record in asthma clinical trials, coordinate the respiratory translational research collaboration. University of Southampton (Djukanovic, Skipp) bring expertise in severe asthma clinical trials, developing bio-stratification tools in trial (e.g. European IMI funded UBIOPRED consortium) and high throughput urinary proteomics. University of Oxford (Pavord) designed pivotal trials of Mepolizumab in severe asthma. University of Glasgow (Chaudhuri) brings expertise in asthma trials and coordinates the clinical trial work package in MRC-RASP. Imperial College (Chung) has expertise acquired via analysis of the UBIOPRED cohort. University of Manchester (Fowler),Barts Health Care Trust (Pfeffer), Royal Brompton Hospital (Menzies-Gow), Birmingham Heartlands Hospital (Mansur), Guys and St Thomas's Hospital (Jackson) and the Universities of Portsmouth (Chauhan), Swansea (Davies), Norwich (Wilson), all have expertise in clinical trial delivery. The MRC CTU at UCL (Parmar and Brown) are leaders in clinical trial methodology and Leicester CTU (Barber) have expertise as a registered CTU providing full trial support and co-ordination of clinical trials. Asthma UK (Walker) has developed a strategic road map for asthma innovation to drive EU funding in asthma (EARIP program). Val Hudson (patient) has expertise in asthma PPI. |
| Impact | None yet. |
| Start Year | 2019 |
| Description | Beyond Allergic TH2 Severe Asthma (BEAT EME) |
| Organisation | Medical Research Council (MRC) |
| Department | MRC Clinical Trials Unit |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Expertise as coordinator of MRC-RASP program. |
| Collaborator Contribution | Universities of Leicester (Siddiqui-Coordinator, Brightling, Wardlaw) bring expertise in program management, bio sample tracking, phenotyping, clinical trials, sputum profiling, eosinophil biology, clinical microbiomics and have links to their molecular pathology node. University of Nottingham (Shaw, Harrison) have a track record in asthma clinical trials, coordinate the respiratory translational research collaboration. University of Southampton (Djukanovic, Skipp) bring expertise in severe asthma clinical trials, developing bio-stratification tools in trial (e.g. European IMI funded UBIOPRED consortium) and high throughput urinary proteomics. University of Oxford (Pavord) designed pivotal trials of Mepolizumab in severe asthma. University of Glasgow (Chaudhuri) brings expertise in asthma trials and coordinates the clinical trial work package in MRC-RASP. Imperial College (Chung) has expertise acquired via analysis of the UBIOPRED cohort. University of Manchester (Fowler),Barts Health Care Trust (Pfeffer), Royal Brompton Hospital (Menzies-Gow), Birmingham Heartlands Hospital (Mansur), Guys and St Thomas's Hospital (Jackson) and the Universities of Portsmouth (Chauhan), Swansea (Davies), Norwich (Wilson), all have expertise in clinical trial delivery. The MRC CTU at UCL (Parmar and Brown) are leaders in clinical trial methodology and Leicester CTU (Barber) have expertise as a registered CTU providing full trial support and co-ordination of clinical trials. Asthma UK (Walker) has developed a strategic road map for asthma innovation to drive EU funding in asthma (EARIP program). Val Hudson (patient) has expertise in asthma PPI. |
| Impact | None yet. |
| Start Year | 2019 |
| Description | Beyond Allergic TH2 Severe Asthma (BEAT EME) |
| Organisation | Portsmouth Hospitals NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Expertise as coordinator of MRC-RASP program. |
| Collaborator Contribution | Universities of Leicester (Siddiqui-Coordinator, Brightling, Wardlaw) bring expertise in program management, bio sample tracking, phenotyping, clinical trials, sputum profiling, eosinophil biology, clinical microbiomics and have links to their molecular pathology node. University of Nottingham (Shaw, Harrison) have a track record in asthma clinical trials, coordinate the respiratory translational research collaboration. University of Southampton (Djukanovic, Skipp) bring expertise in severe asthma clinical trials, developing bio-stratification tools in trial (e.g. European IMI funded UBIOPRED consortium) and high throughput urinary proteomics. University of Oxford (Pavord) designed pivotal trials of Mepolizumab in severe asthma. University of Glasgow (Chaudhuri) brings expertise in asthma trials and coordinates the clinical trial work package in MRC-RASP. Imperial College (Chung) has expertise acquired via analysis of the UBIOPRED cohort. University of Manchester (Fowler),Barts Health Care Trust (Pfeffer), Royal Brompton Hospital (Menzies-Gow), Birmingham Heartlands Hospital (Mansur), Guys and St Thomas's Hospital (Jackson) and the Universities of Portsmouth (Chauhan), Swansea (Davies), Norwich (Wilson), all have expertise in clinical trial delivery. The MRC CTU at UCL (Parmar and Brown) are leaders in clinical trial methodology and Leicester CTU (Barber) have expertise as a registered CTU providing full trial support and co-ordination of clinical trials. Asthma UK (Walker) has developed a strategic road map for asthma innovation to drive EU funding in asthma (EARIP program). Val Hudson (patient) has expertise in asthma PPI. |
| Impact | None yet. |
| Start Year | 2019 |
| Description | Beyond Allergic TH2 Severe Asthma (BEAT EME) |
| Organisation | Royal Brompton & Harefield NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Expertise as coordinator of MRC-RASP program. |
| Collaborator Contribution | Universities of Leicester (Siddiqui-Coordinator, Brightling, Wardlaw) bring expertise in program management, bio sample tracking, phenotyping, clinical trials, sputum profiling, eosinophil biology, clinical microbiomics and have links to their molecular pathology node. University of Nottingham (Shaw, Harrison) have a track record in asthma clinical trials, coordinate the respiratory translational research collaboration. University of Southampton (Djukanovic, Skipp) bring expertise in severe asthma clinical trials, developing bio-stratification tools in trial (e.g. European IMI funded UBIOPRED consortium) and high throughput urinary proteomics. University of Oxford (Pavord) designed pivotal trials of Mepolizumab in severe asthma. University of Glasgow (Chaudhuri) brings expertise in asthma trials and coordinates the clinical trial work package in MRC-RASP. Imperial College (Chung) has expertise acquired via analysis of the UBIOPRED cohort. University of Manchester (Fowler),Barts Health Care Trust (Pfeffer), Royal Brompton Hospital (Menzies-Gow), Birmingham Heartlands Hospital (Mansur), Guys and St Thomas's Hospital (Jackson) and the Universities of Portsmouth (Chauhan), Swansea (Davies), Norwich (Wilson), all have expertise in clinical trial delivery. The MRC CTU at UCL (Parmar and Brown) are leaders in clinical trial methodology and Leicester CTU (Barber) have expertise as a registered CTU providing full trial support and co-ordination of clinical trials. Asthma UK (Walker) has developed a strategic road map for asthma innovation to drive EU funding in asthma (EARIP program). Val Hudson (patient) has expertise in asthma PPI. |
| Impact | None yet. |
| Start Year | 2019 |
| Description | Beyond Allergic TH2 Severe Asthma (BEAT EME) |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Expertise as coordinator of MRC-RASP program. |
| Collaborator Contribution | Universities of Leicester (Siddiqui-Coordinator, Brightling, Wardlaw) bring expertise in program management, bio sample tracking, phenotyping, clinical trials, sputum profiling, eosinophil biology, clinical microbiomics and have links to their molecular pathology node. University of Nottingham (Shaw, Harrison) have a track record in asthma clinical trials, coordinate the respiratory translational research collaboration. University of Southampton (Djukanovic, Skipp) bring expertise in severe asthma clinical trials, developing bio-stratification tools in trial (e.g. European IMI funded UBIOPRED consortium) and high throughput urinary proteomics. University of Oxford (Pavord) designed pivotal trials of Mepolizumab in severe asthma. University of Glasgow (Chaudhuri) brings expertise in asthma trials and coordinates the clinical trial work package in MRC-RASP. Imperial College (Chung) has expertise acquired via analysis of the UBIOPRED cohort. University of Manchester (Fowler),Barts Health Care Trust (Pfeffer), Royal Brompton Hospital (Menzies-Gow), Birmingham Heartlands Hospital (Mansur), Guys and St Thomas's Hospital (Jackson) and the Universities of Portsmouth (Chauhan), Swansea (Davies), Norwich (Wilson), all have expertise in clinical trial delivery. The MRC CTU at UCL (Parmar and Brown) are leaders in clinical trial methodology and Leicester CTU (Barber) have expertise as a registered CTU providing full trial support and co-ordination of clinical trials. Asthma UK (Walker) has developed a strategic road map for asthma innovation to drive EU funding in asthma (EARIP program). Val Hudson (patient) has expertise in asthma PPI. |
| Impact | None yet. |
| Start Year | 2019 |
| Description | Beyond Allergic TH2 Severe Asthma (BEAT EME) |
| Organisation | University of Leicester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Expertise as coordinator of MRC-RASP program. |
| Collaborator Contribution | Universities of Leicester (Siddiqui-Coordinator, Brightling, Wardlaw) bring expertise in program management, bio sample tracking, phenotyping, clinical trials, sputum profiling, eosinophil biology, clinical microbiomics and have links to their molecular pathology node. University of Nottingham (Shaw, Harrison) have a track record in asthma clinical trials, coordinate the respiratory translational research collaboration. University of Southampton (Djukanovic, Skipp) bring expertise in severe asthma clinical trials, developing bio-stratification tools in trial (e.g. European IMI funded UBIOPRED consortium) and high throughput urinary proteomics. University of Oxford (Pavord) designed pivotal trials of Mepolizumab in severe asthma. University of Glasgow (Chaudhuri) brings expertise in asthma trials and coordinates the clinical trial work package in MRC-RASP. Imperial College (Chung) has expertise acquired via analysis of the UBIOPRED cohort. University of Manchester (Fowler),Barts Health Care Trust (Pfeffer), Royal Brompton Hospital (Menzies-Gow), Birmingham Heartlands Hospital (Mansur), Guys and St Thomas's Hospital (Jackson) and the Universities of Portsmouth (Chauhan), Swansea (Davies), Norwich (Wilson), all have expertise in clinical trial delivery. The MRC CTU at UCL (Parmar and Brown) are leaders in clinical trial methodology and Leicester CTU (Barber) have expertise as a registered CTU providing full trial support and co-ordination of clinical trials. Asthma UK (Walker) has developed a strategic road map for asthma innovation to drive EU funding in asthma (EARIP program). Val Hudson (patient) has expertise in asthma PPI. |
| Impact | None yet. |
| Start Year | 2019 |
| Description | Beyond Allergic TH2 Severe Asthma (BEAT EME) |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Expertise as coordinator of MRC-RASP program. |
| Collaborator Contribution | Universities of Leicester (Siddiqui-Coordinator, Brightling, Wardlaw) bring expertise in program management, bio sample tracking, phenotyping, clinical trials, sputum profiling, eosinophil biology, clinical microbiomics and have links to their molecular pathology node. University of Nottingham (Shaw, Harrison) have a track record in asthma clinical trials, coordinate the respiratory translational research collaboration. University of Southampton (Djukanovic, Skipp) bring expertise in severe asthma clinical trials, developing bio-stratification tools in trial (e.g. European IMI funded UBIOPRED consortium) and high throughput urinary proteomics. University of Oxford (Pavord) designed pivotal trials of Mepolizumab in severe asthma. University of Glasgow (Chaudhuri) brings expertise in asthma trials and coordinates the clinical trial work package in MRC-RASP. Imperial College (Chung) has expertise acquired via analysis of the UBIOPRED cohort. University of Manchester (Fowler),Barts Health Care Trust (Pfeffer), Royal Brompton Hospital (Menzies-Gow), Birmingham Heartlands Hospital (Mansur), Guys and St Thomas's Hospital (Jackson) and the Universities of Portsmouth (Chauhan), Swansea (Davies), Norwich (Wilson), all have expertise in clinical trial delivery. The MRC CTU at UCL (Parmar and Brown) are leaders in clinical trial methodology and Leicester CTU (Barber) have expertise as a registered CTU providing full trial support and co-ordination of clinical trials. Asthma UK (Walker) has developed a strategic road map for asthma innovation to drive EU funding in asthma (EARIP program). Val Hudson (patient) has expertise in asthma PPI. |
| Impact | None yet. |
| Start Year | 2019 |
| Description | Beyond Allergic TH2 Severe Asthma (BEAT EME) |
| Organisation | University of Nottingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Expertise as coordinator of MRC-RASP program. |
| Collaborator Contribution | Universities of Leicester (Siddiqui-Coordinator, Brightling, Wardlaw) bring expertise in program management, bio sample tracking, phenotyping, clinical trials, sputum profiling, eosinophil biology, clinical microbiomics and have links to their molecular pathology node. University of Nottingham (Shaw, Harrison) have a track record in asthma clinical trials, coordinate the respiratory translational research collaboration. University of Southampton (Djukanovic, Skipp) bring expertise in severe asthma clinical trials, developing bio-stratification tools in trial (e.g. European IMI funded UBIOPRED consortium) and high throughput urinary proteomics. University of Oxford (Pavord) designed pivotal trials of Mepolizumab in severe asthma. University of Glasgow (Chaudhuri) brings expertise in asthma trials and coordinates the clinical trial work package in MRC-RASP. Imperial College (Chung) has expertise acquired via analysis of the UBIOPRED cohort. University of Manchester (Fowler),Barts Health Care Trust (Pfeffer), Royal Brompton Hospital (Menzies-Gow), Birmingham Heartlands Hospital (Mansur), Guys and St Thomas's Hospital (Jackson) and the Universities of Portsmouth (Chauhan), Swansea (Davies), Norwich (Wilson), all have expertise in clinical trial delivery. The MRC CTU at UCL (Parmar and Brown) are leaders in clinical trial methodology and Leicester CTU (Barber) have expertise as a registered CTU providing full trial support and co-ordination of clinical trials. Asthma UK (Walker) has developed a strategic road map for asthma innovation to drive EU funding in asthma (EARIP program). Val Hudson (patient) has expertise in asthma PPI. |
| Impact | None yet. |
| Start Year | 2019 |
| Description | Beyond Allergic TH2 Severe Asthma (BEAT EME) |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Expertise as coordinator of MRC-RASP program. |
| Collaborator Contribution | Universities of Leicester (Siddiqui-Coordinator, Brightling, Wardlaw) bring expertise in program management, bio sample tracking, phenotyping, clinical trials, sputum profiling, eosinophil biology, clinical microbiomics and have links to their molecular pathology node. University of Nottingham (Shaw, Harrison) have a track record in asthma clinical trials, coordinate the respiratory translational research collaboration. University of Southampton (Djukanovic, Skipp) bring expertise in severe asthma clinical trials, developing bio-stratification tools in trial (e.g. European IMI funded UBIOPRED consortium) and high throughput urinary proteomics. University of Oxford (Pavord) designed pivotal trials of Mepolizumab in severe asthma. University of Glasgow (Chaudhuri) brings expertise in asthma trials and coordinates the clinical trial work package in MRC-RASP. Imperial College (Chung) has expertise acquired via analysis of the UBIOPRED cohort. University of Manchester (Fowler),Barts Health Care Trust (Pfeffer), Royal Brompton Hospital (Menzies-Gow), Birmingham Heartlands Hospital (Mansur), Guys and St Thomas's Hospital (Jackson) and the Universities of Portsmouth (Chauhan), Swansea (Davies), Norwich (Wilson), all have expertise in clinical trial delivery. The MRC CTU at UCL (Parmar and Brown) are leaders in clinical trial methodology and Leicester CTU (Barber) have expertise as a registered CTU providing full trial support and co-ordination of clinical trials. Asthma UK (Walker) has developed a strategic road map for asthma innovation to drive EU funding in asthma (EARIP program). Val Hudson (patient) has expertise in asthma PPI. |
| Impact | None yet. |
| Start Year | 2019 |
| Description | Beyond Allergic TH2 Severe Asthma (BEAT EME) |
| Organisation | University of Southampton |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Expertise as coordinator of MRC-RASP program. |
| Collaborator Contribution | Universities of Leicester (Siddiqui-Coordinator, Brightling, Wardlaw) bring expertise in program management, bio sample tracking, phenotyping, clinical trials, sputum profiling, eosinophil biology, clinical microbiomics and have links to their molecular pathology node. University of Nottingham (Shaw, Harrison) have a track record in asthma clinical trials, coordinate the respiratory translational research collaboration. University of Southampton (Djukanovic, Skipp) bring expertise in severe asthma clinical trials, developing bio-stratification tools in trial (e.g. European IMI funded UBIOPRED consortium) and high throughput urinary proteomics. University of Oxford (Pavord) designed pivotal trials of Mepolizumab in severe asthma. University of Glasgow (Chaudhuri) brings expertise in asthma trials and coordinates the clinical trial work package in MRC-RASP. Imperial College (Chung) has expertise acquired via analysis of the UBIOPRED cohort. University of Manchester (Fowler),Barts Health Care Trust (Pfeffer), Royal Brompton Hospital (Menzies-Gow), Birmingham Heartlands Hospital (Mansur), Guys and St Thomas's Hospital (Jackson) and the Universities of Portsmouth (Chauhan), Swansea (Davies), Norwich (Wilson), all have expertise in clinical trial delivery. The MRC CTU at UCL (Parmar and Brown) are leaders in clinical trial methodology and Leicester CTU (Barber) have expertise as a registered CTU providing full trial support and co-ordination of clinical trials. Asthma UK (Walker) has developed a strategic road map for asthma innovation to drive EU funding in asthma (EARIP program). Val Hudson (patient) has expertise in asthma PPI. |
| Impact | None yet. |
| Start Year | 2019 |
| Description | INTERREG CHITIN Award Cross-border Healthcare Intervention Trials in Ireland Network |
| Organisation | Belfast City Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | The value of the cross border element of this work is the sharing of clinical knowledge between two jurisdictions that are on a same island. These jurisdictions are separated by two different health systems which affect the access to care, the funding of health care and the background and training experiences of the clinical teams. By engaging in research using digital technology the project offers value to both health services by providing information for planning service design on both sides of the border. Hence, one of the key outcomes of the work will be to understand the how patients, clinicians and management systems view this technology. There is a shared interest in patient management and novel strategies to overcome the problem of non-adherence in asthma patients between the North and South that has resulted in a formal collaboration between Queens University Belfast and Royal College of Surgeons in Ireland. We are conducting the INCA_Sun protocol in these two sites. This would be the perfect opportunity to share lessons learnt and develop further projects. Professor Heaney has developed the FeNo suppression test and is the lead for the MRC RASP study in which this is a central feature. The FeNO suppression test is part of the INCA Sun project. Professor Heaney is recognised as a world authority in the severe asthma and is a central part of the INCA adherence project. . The method of assessing the interaction of adherence and the biomarker or airway inflammation, FeNO, developed by Professor Heaney represents an important concept in how to assess the interaction of biomarkers relevant to airway inflammation. |
| Collaborator Contribution | This team of researchers in the Royal College of Surgeons in Ireland and Trinity College Dublin developed a small device that is attached to a Diskus inhaler. The device called INCA (Inhaler Compliance Assessment) electronically records the timing and inhaler technique when the diskus is used. Information on a microchip in the device allows both the doctor and the patient to track how the inhaler is being used. Drs Hayes (Cavan Monaghan RCSI Hospitals network) and Dr Counihan (Droghdea and Dundalk RCSI Hospitals network) are Consultant Chest Physicians. Each of these physicians has a close working relationship with the RCSI/INCA/Costello team, both through established informal clinical referral pathways and as clinicians who are part of the RCSI Hospitals network. Each of these clinicians has a dedicated respiratory multi-disciplinary care team of nurses, physiotherapists and pulmonary physiologists. Hence, the appropriate support teams and environment are in place. We anticipate the trials nurses will work embedded within these services, as we have previously done at other centres. Drs McManus, Hayes and Moan in the Southern and Western Health & Social Care Trust Hospitals also have at their centres dedicated respiratory multi-disciplinary care team of nurses, physiotherapists and pulmonary physiologists. They too have a close working relationship and referral pathway to Professor Heaney's clinic at the Belfast City Hospital. |
| Impact | None as yet. |
| Start Year | 2018 |
| Description | INTERREG CHITIN Award Cross-border Healthcare Intervention Trials in Ireland Network |
| Organisation | Cavan General Hospital |
| Country | Ireland |
| Sector | Hospitals |
| PI Contribution | The value of the cross border element of this work is the sharing of clinical knowledge between two jurisdictions that are on a same island. These jurisdictions are separated by two different health systems which affect the access to care, the funding of health care and the background and training experiences of the clinical teams. By engaging in research using digital technology the project offers value to both health services by providing information for planning service design on both sides of the border. Hence, one of the key outcomes of the work will be to understand the how patients, clinicians and management systems view this technology. There is a shared interest in patient management and novel strategies to overcome the problem of non-adherence in asthma patients between the North and South that has resulted in a formal collaboration between Queens University Belfast and Royal College of Surgeons in Ireland. We are conducting the INCA_Sun protocol in these two sites. This would be the perfect opportunity to share lessons learnt and develop further projects. Professor Heaney has developed the FeNo suppression test and is the lead for the MRC RASP study in which this is a central feature. The FeNO suppression test is part of the INCA Sun project. Professor Heaney is recognised as a world authority in the severe asthma and is a central part of the INCA adherence project. . The method of assessing the interaction of adherence and the biomarker or airway inflammation, FeNO, developed by Professor Heaney represents an important concept in how to assess the interaction of biomarkers relevant to airway inflammation. |
| Collaborator Contribution | This team of researchers in the Royal College of Surgeons in Ireland and Trinity College Dublin developed a small device that is attached to a Diskus inhaler. The device called INCA (Inhaler Compliance Assessment) electronically records the timing and inhaler technique when the diskus is used. Information on a microchip in the device allows both the doctor and the patient to track how the inhaler is being used. Drs Hayes (Cavan Monaghan RCSI Hospitals network) and Dr Counihan (Droghdea and Dundalk RCSI Hospitals network) are Consultant Chest Physicians. Each of these physicians has a close working relationship with the RCSI/INCA/Costello team, both through established informal clinical referral pathways and as clinicians who are part of the RCSI Hospitals network. Each of these clinicians has a dedicated respiratory multi-disciplinary care team of nurses, physiotherapists and pulmonary physiologists. Hence, the appropriate support teams and environment are in place. We anticipate the trials nurses will work embedded within these services, as we have previously done at other centres. Drs McManus, Hayes and Moan in the Southern and Western Health & Social Care Trust Hospitals also have at their centres dedicated respiratory multi-disciplinary care team of nurses, physiotherapists and pulmonary physiologists. They too have a close working relationship and referral pathway to Professor Heaney's clinic at the Belfast City Hospital. |
| Impact | None as yet. |
| Start Year | 2018 |
| Description | INTERREG CHITIN Award Cross-border Healthcare Intervention Trials in Ireland Network |
| Organisation | Daisy Hill Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | The value of the cross border element of this work is the sharing of clinical knowledge between two jurisdictions that are on a same island. These jurisdictions are separated by two different health systems which affect the access to care, the funding of health care and the background and training experiences of the clinical teams. By engaging in research using digital technology the project offers value to both health services by providing information for planning service design on both sides of the border. Hence, one of the key outcomes of the work will be to understand the how patients, clinicians and management systems view this technology. There is a shared interest in patient management and novel strategies to overcome the problem of non-adherence in asthma patients between the North and South that has resulted in a formal collaboration between Queens University Belfast and Royal College of Surgeons in Ireland. We are conducting the INCA_Sun protocol in these two sites. This would be the perfect opportunity to share lessons learnt and develop further projects. Professor Heaney has developed the FeNo suppression test and is the lead for the MRC RASP study in which this is a central feature. The FeNO suppression test is part of the INCA Sun project. Professor Heaney is recognised as a world authority in the severe asthma and is a central part of the INCA adherence project. . The method of assessing the interaction of adherence and the biomarker or airway inflammation, FeNO, developed by Professor Heaney represents an important concept in how to assess the interaction of biomarkers relevant to airway inflammation. |
| Collaborator Contribution | This team of researchers in the Royal College of Surgeons in Ireland and Trinity College Dublin developed a small device that is attached to a Diskus inhaler. The device called INCA (Inhaler Compliance Assessment) electronically records the timing and inhaler technique when the diskus is used. Information on a microchip in the device allows both the doctor and the patient to track how the inhaler is being used. Drs Hayes (Cavan Monaghan RCSI Hospitals network) and Dr Counihan (Droghdea and Dundalk RCSI Hospitals network) are Consultant Chest Physicians. Each of these physicians has a close working relationship with the RCSI/INCA/Costello team, both through established informal clinical referral pathways and as clinicians who are part of the RCSI Hospitals network. Each of these clinicians has a dedicated respiratory multi-disciplinary care team of nurses, physiotherapists and pulmonary physiologists. Hence, the appropriate support teams and environment are in place. We anticipate the trials nurses will work embedded within these services, as we have previously done at other centres. Drs McManus, Hayes and Moan in the Southern and Western Health & Social Care Trust Hospitals also have at their centres dedicated respiratory multi-disciplinary care team of nurses, physiotherapists and pulmonary physiologists. They too have a close working relationship and referral pathway to Professor Heaney's clinic at the Belfast City Hospital. |
| Impact | None as yet. |
| Start Year | 2018 |
| Description | INTERREG CHITIN Award Cross-border Healthcare Intervention Trials in Ireland Network |
| Organisation | Letterkenny General Hospital |
| Country | Ireland |
| Sector | Hospitals |
| PI Contribution | The value of the cross border element of this work is the sharing of clinical knowledge between two jurisdictions that are on a same island. These jurisdictions are separated by two different health systems which affect the access to care, the funding of health care and the background and training experiences of the clinical teams. By engaging in research using digital technology the project offers value to both health services by providing information for planning service design on both sides of the border. Hence, one of the key outcomes of the work will be to understand the how patients, clinicians and management systems view this technology. There is a shared interest in patient management and novel strategies to overcome the problem of non-adherence in asthma patients between the North and South that has resulted in a formal collaboration between Queens University Belfast and Royal College of Surgeons in Ireland. We are conducting the INCA_Sun protocol in these two sites. This would be the perfect opportunity to share lessons learnt and develop further projects. Professor Heaney has developed the FeNo suppression test and is the lead for the MRC RASP study in which this is a central feature. The FeNO suppression test is part of the INCA Sun project. Professor Heaney is recognised as a world authority in the severe asthma and is a central part of the INCA adherence project. . The method of assessing the interaction of adherence and the biomarker or airway inflammation, FeNO, developed by Professor Heaney represents an important concept in how to assess the interaction of biomarkers relevant to airway inflammation. |
| Collaborator Contribution | This team of researchers in the Royal College of Surgeons in Ireland and Trinity College Dublin developed a small device that is attached to a Diskus inhaler. The device called INCA (Inhaler Compliance Assessment) electronically records the timing and inhaler technique when the diskus is used. Information on a microchip in the device allows both the doctor and the patient to track how the inhaler is being used. Drs Hayes (Cavan Monaghan RCSI Hospitals network) and Dr Counihan (Droghdea and Dundalk RCSI Hospitals network) are Consultant Chest Physicians. Each of these physicians has a close working relationship with the RCSI/INCA/Costello team, both through established informal clinical referral pathways and as clinicians who are part of the RCSI Hospitals network. Each of these clinicians has a dedicated respiratory multi-disciplinary care team of nurses, physiotherapists and pulmonary physiologists. Hence, the appropriate support teams and environment are in place. We anticipate the trials nurses will work embedded within these services, as we have previously done at other centres. Drs McManus, Hayes and Moan in the Southern and Western Health & Social Care Trust Hospitals also have at their centres dedicated respiratory multi-disciplinary care team of nurses, physiotherapists and pulmonary physiologists. They too have a close working relationship and referral pathway to Professor Heaney's clinic at the Belfast City Hospital. |
| Impact | None as yet. |
| Start Year | 2018 |
| Description | INTERREG CHITIN Award Cross-border Healthcare Intervention Trials in Ireland Network |
| Organisation | Our Lady of Lourdes Hospital |
| Country | Ireland |
| Sector | Hospitals |
| PI Contribution | The value of the cross border element of this work is the sharing of clinical knowledge between two jurisdictions that are on a same island. These jurisdictions are separated by two different health systems which affect the access to care, the funding of health care and the background and training experiences of the clinical teams. By engaging in research using digital technology the project offers value to both health services by providing information for planning service design on both sides of the border. Hence, one of the key outcomes of the work will be to understand the how patients, clinicians and management systems view this technology. There is a shared interest in patient management and novel strategies to overcome the problem of non-adherence in asthma patients between the North and South that has resulted in a formal collaboration between Queens University Belfast and Royal College of Surgeons in Ireland. We are conducting the INCA_Sun protocol in these two sites. This would be the perfect opportunity to share lessons learnt and develop further projects. Professor Heaney has developed the FeNo suppression test and is the lead for the MRC RASP study in which this is a central feature. The FeNO suppression test is part of the INCA Sun project. Professor Heaney is recognised as a world authority in the severe asthma and is a central part of the INCA adherence project. . The method of assessing the interaction of adherence and the biomarker or airway inflammation, FeNO, developed by Professor Heaney represents an important concept in how to assess the interaction of biomarkers relevant to airway inflammation. |
| Collaborator Contribution | This team of researchers in the Royal College of Surgeons in Ireland and Trinity College Dublin developed a small device that is attached to a Diskus inhaler. The device called INCA (Inhaler Compliance Assessment) electronically records the timing and inhaler technique when the diskus is used. Information on a microchip in the device allows both the doctor and the patient to track how the inhaler is being used. Drs Hayes (Cavan Monaghan RCSI Hospitals network) and Dr Counihan (Droghdea and Dundalk RCSI Hospitals network) are Consultant Chest Physicians. Each of these physicians has a close working relationship with the RCSI/INCA/Costello team, both through established informal clinical referral pathways and as clinicians who are part of the RCSI Hospitals network. Each of these clinicians has a dedicated respiratory multi-disciplinary care team of nurses, physiotherapists and pulmonary physiologists. Hence, the appropriate support teams and environment are in place. We anticipate the trials nurses will work embedded within these services, as we have previously done at other centres. Drs McManus, Hayes and Moan in the Southern and Western Health & Social Care Trust Hospitals also have at their centres dedicated respiratory multi-disciplinary care team of nurses, physiotherapists and pulmonary physiologists. They too have a close working relationship and referral pathway to Professor Heaney's clinic at the Belfast City Hospital. |
| Impact | None as yet. |
| Start Year | 2018 |
| Description | INTERREG CHITIN Award Cross-border Healthcare Intervention Trials in Ireland Network |
| Organisation | Royal College of Surgeons in Ireland |
| Country | Ireland |
| Sector | Academic/University |
| PI Contribution | The value of the cross border element of this work is the sharing of clinical knowledge between two jurisdictions that are on a same island. These jurisdictions are separated by two different health systems which affect the access to care, the funding of health care and the background and training experiences of the clinical teams. By engaging in research using digital technology the project offers value to both health services by providing information for planning service design on both sides of the border. Hence, one of the key outcomes of the work will be to understand the how patients, clinicians and management systems view this technology. There is a shared interest in patient management and novel strategies to overcome the problem of non-adherence in asthma patients between the North and South that has resulted in a formal collaboration between Queens University Belfast and Royal College of Surgeons in Ireland. We are conducting the INCA_Sun protocol in these two sites. This would be the perfect opportunity to share lessons learnt and develop further projects. Professor Heaney has developed the FeNo suppression test and is the lead for the MRC RASP study in which this is a central feature. The FeNO suppression test is part of the INCA Sun project. Professor Heaney is recognised as a world authority in the severe asthma and is a central part of the INCA adherence project. . The method of assessing the interaction of adherence and the biomarker or airway inflammation, FeNO, developed by Professor Heaney represents an important concept in how to assess the interaction of biomarkers relevant to airway inflammation. |
| Collaborator Contribution | This team of researchers in the Royal College of Surgeons in Ireland and Trinity College Dublin developed a small device that is attached to a Diskus inhaler. The device called INCA (Inhaler Compliance Assessment) electronically records the timing and inhaler technique when the diskus is used. Information on a microchip in the device allows both the doctor and the patient to track how the inhaler is being used. Drs Hayes (Cavan Monaghan RCSI Hospitals network) and Dr Counihan (Droghdea and Dundalk RCSI Hospitals network) are Consultant Chest Physicians. Each of these physicians has a close working relationship with the RCSI/INCA/Costello team, both through established informal clinical referral pathways and as clinicians who are part of the RCSI Hospitals network. Each of these clinicians has a dedicated respiratory multi-disciplinary care team of nurses, physiotherapists and pulmonary physiologists. Hence, the appropriate support teams and environment are in place. We anticipate the trials nurses will work embedded within these services, as we have previously done at other centres. Drs McManus, Hayes and Moan in the Southern and Western Health & Social Care Trust Hospitals also have at their centres dedicated respiratory multi-disciplinary care team of nurses, physiotherapists and pulmonary physiologists. They too have a close working relationship and referral pathway to Professor Heaney's clinic at the Belfast City Hospital. |
| Impact | None as yet. |
| Start Year | 2018 |
| Description | INTERREG CHITIN Award Cross-border Healthcare Intervention Trials in Ireland Network |
| Organisation | South West Acute Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | The value of the cross border element of this work is the sharing of clinical knowledge between two jurisdictions that are on a same island. These jurisdictions are separated by two different health systems which affect the access to care, the funding of health care and the background and training experiences of the clinical teams. By engaging in research using digital technology the project offers value to both health services by providing information for planning service design on both sides of the border. Hence, one of the key outcomes of the work will be to understand the how patients, clinicians and management systems view this technology. There is a shared interest in patient management and novel strategies to overcome the problem of non-adherence in asthma patients between the North and South that has resulted in a formal collaboration between Queens University Belfast and Royal College of Surgeons in Ireland. We are conducting the INCA_Sun protocol in these two sites. This would be the perfect opportunity to share lessons learnt and develop further projects. Professor Heaney has developed the FeNo suppression test and is the lead for the MRC RASP study in which this is a central feature. The FeNO suppression test is part of the INCA Sun project. Professor Heaney is recognised as a world authority in the severe asthma and is a central part of the INCA adherence project. . The method of assessing the interaction of adherence and the biomarker or airway inflammation, FeNO, developed by Professor Heaney represents an important concept in how to assess the interaction of biomarkers relevant to airway inflammation. |
| Collaborator Contribution | This team of researchers in the Royal College of Surgeons in Ireland and Trinity College Dublin developed a small device that is attached to a Diskus inhaler. The device called INCA (Inhaler Compliance Assessment) electronically records the timing and inhaler technique when the diskus is used. Information on a microchip in the device allows both the doctor and the patient to track how the inhaler is being used. Drs Hayes (Cavan Monaghan RCSI Hospitals network) and Dr Counihan (Droghdea and Dundalk RCSI Hospitals network) are Consultant Chest Physicians. Each of these physicians has a close working relationship with the RCSI/INCA/Costello team, both through established informal clinical referral pathways and as clinicians who are part of the RCSI Hospitals network. Each of these clinicians has a dedicated respiratory multi-disciplinary care team of nurses, physiotherapists and pulmonary physiologists. Hence, the appropriate support teams and environment are in place. We anticipate the trials nurses will work embedded within these services, as we have previously done at other centres. Drs McManus, Hayes and Moan in the Southern and Western Health & Social Care Trust Hospitals also have at their centres dedicated respiratory multi-disciplinary care team of nurses, physiotherapists and pulmonary physiologists. They too have a close working relationship and referral pathway to Professor Heaney's clinic at the Belfast City Hospital. |
| Impact | None as yet. |
| Start Year | 2018 |
| Description | RASP UK Consortium |
| Organisation | Aerocrine |
| Country | Sweden |
| Sector | Private |
| PI Contribution | Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers. |
| Collaborator Contribution | The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED. The RASP-UK legacy Committee has been established to ensure that all data and samples from the RASP-UK programme will continue to serve a scientifically and ethically just purpose, including managing requests from external sources outside of the RASP-UK programme for the use of the RASP-UK trial data and/or samples stored for future ethically approved research. The clinical and omics data sets of RASP-UK have been successfully uploaded to the tranSMART platform, which platform enables real-time analyses. It has been aligned with the UBIOPRED and SOMOSA datasets and ensures accessibility, sustainability and transparency of data which is essential for future respiratory projects within the EU and the UK. Requests for accessing the RASP-UK data management platform will be managed by the RASP-UK Legacy Committee. |
| Impact | Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015 |
| Start Year | 2015 |
| Description | RASP UK Consortium |
| Organisation | Amgen Inc |
| Country | United States |
| Sector | Private |
| PI Contribution | Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers. |
| Collaborator Contribution | The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED. The RASP-UK legacy Committee has been established to ensure that all data and samples from the RASP-UK programme will continue to serve a scientifically and ethically just purpose, including managing requests from external sources outside of the RASP-UK programme for the use of the RASP-UK trial data and/or samples stored for future ethically approved research. The clinical and omics data sets of RASP-UK have been successfully uploaded to the tranSMART platform, which platform enables real-time analyses. It has been aligned with the UBIOPRED and SOMOSA datasets and ensures accessibility, sustainability and transparency of data which is essential for future respiratory projects within the EU and the UK. Requests for accessing the RASP-UK data management platform will be managed by the RASP-UK Legacy Committee. |
| Impact | Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015 |
| Start Year | 2015 |
| Description | RASP UK Consortium |
| Organisation | Asthma + Lung UK |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers. |
| Collaborator Contribution | The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED. The RASP-UK legacy Committee has been established to ensure that all data and samples from the RASP-UK programme will continue to serve a scientifically and ethically just purpose, including managing requests from external sources outside of the RASP-UK programme for the use of the RASP-UK trial data and/or samples stored for future ethically approved research. The clinical and omics data sets of RASP-UK have been successfully uploaded to the tranSMART platform, which platform enables real-time analyses. It has been aligned with the UBIOPRED and SOMOSA datasets and ensures accessibility, sustainability and transparency of data which is essential for future respiratory projects within the EU and the UK. Requests for accessing the RASP-UK data management platform will be managed by the RASP-UK Legacy Committee. |
| Impact | Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015 |
| Start Year | 2015 |
| Description | RASP UK Consortium |
| Organisation | AstraZeneca |
| Department | MedImmune |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers. |
| Collaborator Contribution | The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED. The RASP-UK legacy Committee has been established to ensure that all data and samples from the RASP-UK programme will continue to serve a scientifically and ethically just purpose, including managing requests from external sources outside of the RASP-UK programme for the use of the RASP-UK trial data and/or samples stored for future ethically approved research. The clinical and omics data sets of RASP-UK have been successfully uploaded to the tranSMART platform, which platform enables real-time analyses. It has been aligned with the UBIOPRED and SOMOSA datasets and ensures accessibility, sustainability and transparency of data which is essential for future respiratory projects within the EU and the UK. Requests for accessing the RASP-UK data management platform will be managed by the RASP-UK Legacy Committee. |
| Impact | Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015 |
| Start Year | 2015 |
| Description | RASP UK Consortium |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers. |
| Collaborator Contribution | The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED. The RASP-UK legacy Committee has been established to ensure that all data and samples from the RASP-UK programme will continue to serve a scientifically and ethically just purpose, including managing requests from external sources outside of the RASP-UK programme for the use of the RASP-UK trial data and/or samples stored for future ethically approved research. The clinical and omics data sets of RASP-UK have been successfully uploaded to the tranSMART platform, which platform enables real-time analyses. It has been aligned with the UBIOPRED and SOMOSA datasets and ensures accessibility, sustainability and transparency of data which is essential for future respiratory projects within the EU and the UK. Requests for accessing the RASP-UK data management platform will be managed by the RASP-UK Legacy Committee. |
| Impact | Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015 |
| Start Year | 2015 |
| Description | RASP UK Consortium |
| Organisation | Boehringer Ingelheim |
| Country | Germany |
| Sector | Private |
| PI Contribution | Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers. |
| Collaborator Contribution | The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED. The RASP-UK legacy Committee has been established to ensure that all data and samples from the RASP-UK programme will continue to serve a scientifically and ethically just purpose, including managing requests from external sources outside of the RASP-UK programme for the use of the RASP-UK trial data and/or samples stored for future ethically approved research. The clinical and omics data sets of RASP-UK have been successfully uploaded to the tranSMART platform, which platform enables real-time analyses. It has been aligned with the UBIOPRED and SOMOSA datasets and ensures accessibility, sustainability and transparency of data which is essential for future respiratory projects within the EU and the UK. Requests for accessing the RASP-UK data management platform will be managed by the RASP-UK Legacy Committee. |
| Impact | Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015 |
| Start Year | 2015 |
| Description | RASP UK Consortium |
| Organisation | Genentech, Inc |
| Country | United States |
| Sector | Private |
| PI Contribution | Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers. |
| Collaborator Contribution | The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED. The RASP-UK legacy Committee has been established to ensure that all data and samples from the RASP-UK programme will continue to serve a scientifically and ethically just purpose, including managing requests from external sources outside of the RASP-UK programme for the use of the RASP-UK trial data and/or samples stored for future ethically approved research. The clinical and omics data sets of RASP-UK have been successfully uploaded to the tranSMART platform, which platform enables real-time analyses. It has been aligned with the UBIOPRED and SOMOSA datasets and ensures accessibility, sustainability and transparency of data which is essential for future respiratory projects within the EU and the UK. Requests for accessing the RASP-UK data management platform will be managed by the RASP-UK Legacy Committee. |
| Impact | Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015 |
| Start Year | 2015 |
| Description | RASP UK Consortium |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers. |
| Collaborator Contribution | The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED. The RASP-UK legacy Committee has been established to ensure that all data and samples from the RASP-UK programme will continue to serve a scientifically and ethically just purpose, including managing requests from external sources outside of the RASP-UK programme for the use of the RASP-UK trial data and/or samples stored for future ethically approved research. The clinical and omics data sets of RASP-UK have been successfully uploaded to the tranSMART platform, which platform enables real-time analyses. It has been aligned with the UBIOPRED and SOMOSA datasets and ensures accessibility, sustainability and transparency of data which is essential for future respiratory projects within the EU and the UK. Requests for accessing the RASP-UK data management platform will be managed by the RASP-UK Legacy Committee. |
| Impact | Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015 |
| Start Year | 2015 |
| Description | RASP UK Consortium |
| Organisation | Heart of England NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers. |
| Collaborator Contribution | The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED. The RASP-UK legacy Committee has been established to ensure that all data and samples from the RASP-UK programme will continue to serve a scientifically and ethically just purpose, including managing requests from external sources outside of the RASP-UK programme for the use of the RASP-UK trial data and/or samples stored for future ethically approved research. The clinical and omics data sets of RASP-UK have been successfully uploaded to the tranSMART platform, which platform enables real-time analyses. It has been aligned with the UBIOPRED and SOMOSA datasets and ensures accessibility, sustainability and transparency of data which is essential for future respiratory projects within the EU and the UK. Requests for accessing the RASP-UK data management platform will be managed by the RASP-UK Legacy Committee. |
| Impact | Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015 |
| Start Year | 2015 |
| Description | RASP UK Consortium |
| Organisation | Imperial College London |
| Department | Imperial College Trust |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers. |
| Collaborator Contribution | The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED. The RASP-UK legacy Committee has been established to ensure that all data and samples from the RASP-UK programme will continue to serve a scientifically and ethically just purpose, including managing requests from external sources outside of the RASP-UK programme for the use of the RASP-UK trial data and/or samples stored for future ethically approved research. The clinical and omics data sets of RASP-UK have been successfully uploaded to the tranSMART platform, which platform enables real-time analyses. It has been aligned with the UBIOPRED and SOMOSA datasets and ensures accessibility, sustainability and transparency of data which is essential for future respiratory projects within the EU and the UK. Requests for accessing the RASP-UK data management platform will be managed by the RASP-UK Legacy Committee. |
| Impact | Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015 |
| Start Year | 2015 |
| Description | RASP UK Consortium |
| Organisation | Janssen Research & Development |
| Country | Global |
| Sector | Private |
| PI Contribution | Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers. |
| Collaborator Contribution | The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED. The RASP-UK legacy Committee has been established to ensure that all data and samples from the RASP-UK programme will continue to serve a scientifically and ethically just purpose, including managing requests from external sources outside of the RASP-UK programme for the use of the RASP-UK trial data and/or samples stored for future ethically approved research. The clinical and omics data sets of RASP-UK have been successfully uploaded to the tranSMART platform, which platform enables real-time analyses. It has been aligned with the UBIOPRED and SOMOSA datasets and ensures accessibility, sustainability and transparency of data which is essential for future respiratory projects within the EU and the UK. Requests for accessing the RASP-UK data management platform will be managed by the RASP-UK Legacy Committee. |
| Impact | Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015 |
| Start Year | 2015 |
| Description | RASP UK Consortium |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers. |
| Collaborator Contribution | The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED. The RASP-UK legacy Committee has been established to ensure that all data and samples from the RASP-UK programme will continue to serve a scientifically and ethically just purpose, including managing requests from external sources outside of the RASP-UK programme for the use of the RASP-UK trial data and/or samples stored for future ethically approved research. The clinical and omics data sets of RASP-UK have been successfully uploaded to the tranSMART platform, which platform enables real-time analyses. It has been aligned with the UBIOPRED and SOMOSA datasets and ensures accessibility, sustainability and transparency of data which is essential for future respiratory projects within the EU and the UK. Requests for accessing the RASP-UK data management platform will be managed by the RASP-UK Legacy Committee. |
| Impact | Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015 |
| Start Year | 2015 |
| Description | RASP UK Consortium |
| Organisation | NHS Greater Glasgow and Clyde (NHSGGC) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers. |
| Collaborator Contribution | The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED. The RASP-UK legacy Committee has been established to ensure that all data and samples from the RASP-UK programme will continue to serve a scientifically and ethically just purpose, including managing requests from external sources outside of the RASP-UK programme for the use of the RASP-UK trial data and/or samples stored for future ethically approved research. The clinical and omics data sets of RASP-UK have been successfully uploaded to the tranSMART platform, which platform enables real-time analyses. It has been aligned with the UBIOPRED and SOMOSA datasets and ensures accessibility, sustainability and transparency of data which is essential for future respiratory projects within the EU and the UK. Requests for accessing the RASP-UK data management platform will be managed by the RASP-UK Legacy Committee. |
| Impact | Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015 |
| Start Year | 2015 |
| Description | RASP UK Consortium |
| Organisation | Newcastle upon Tyne Hospitals NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers. |
| Collaborator Contribution | The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED. The RASP-UK legacy Committee has been established to ensure that all data and samples from the RASP-UK programme will continue to serve a scientifically and ethically just purpose, including managing requests from external sources outside of the RASP-UK programme for the use of the RASP-UK trial data and/or samples stored for future ethically approved research. The clinical and omics data sets of RASP-UK have been successfully uploaded to the tranSMART platform, which platform enables real-time analyses. It has been aligned with the UBIOPRED and SOMOSA datasets and ensures accessibility, sustainability and transparency of data which is essential for future respiratory projects within the EU and the UK. Requests for accessing the RASP-UK data management platform will be managed by the RASP-UK Legacy Committee. |
| Impact | Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015 |
| Start Year | 2015 |
| Description | RASP UK Consortium |
| Organisation | Niche.com, Inc. |
| Country | United States |
| Sector | Private |
| PI Contribution | Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers. |
| Collaborator Contribution | The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED. The RASP-UK legacy Committee has been established to ensure that all data and samples from the RASP-UK programme will continue to serve a scientifically and ethically just purpose, including managing requests from external sources outside of the RASP-UK programme for the use of the RASP-UK trial data and/or samples stored for future ethically approved research. The clinical and omics data sets of RASP-UK have been successfully uploaded to the tranSMART platform, which platform enables real-time analyses. It has been aligned with the UBIOPRED and SOMOSA datasets and ensures accessibility, sustainability and transparency of data which is essential for future respiratory projects within the EU and the UK. Requests for accessing the RASP-UK data management platform will be managed by the RASP-UK Legacy Committee. |
| Impact | Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015 |
| Start Year | 2015 |
| Description | RASP UK Consortium |
| Organisation | Royal Brompton Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers. |
| Collaborator Contribution | The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED. The RASP-UK legacy Committee has been established to ensure that all data and samples from the RASP-UK programme will continue to serve a scientifically and ethically just purpose, including managing requests from external sources outside of the RASP-UK programme for the use of the RASP-UK trial data and/or samples stored for future ethically approved research. The clinical and omics data sets of RASP-UK have been successfully uploaded to the tranSMART platform, which platform enables real-time analyses. It has been aligned with the UBIOPRED and SOMOSA datasets and ensures accessibility, sustainability and transparency of data which is essential for future respiratory projects within the EU and the UK. Requests for accessing the RASP-UK data management platform will be managed by the RASP-UK Legacy Committee. |
| Impact | Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015 |
| Start Year | 2015 |
| Description | RASP UK Consortium |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers. |
| Collaborator Contribution | The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED. The RASP-UK legacy Committee has been established to ensure that all data and samples from the RASP-UK programme will continue to serve a scientifically and ethically just purpose, including managing requests from external sources outside of the RASP-UK programme for the use of the RASP-UK trial data and/or samples stored for future ethically approved research. The clinical and omics data sets of RASP-UK have been successfully uploaded to the tranSMART platform, which platform enables real-time analyses. It has been aligned with the UBIOPRED and SOMOSA datasets and ensures accessibility, sustainability and transparency of data which is essential for future respiratory projects within the EU and the UK. Requests for accessing the RASP-UK data management platform will be managed by the RASP-UK Legacy Committee. |
| Impact | Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015 |
| Start Year | 2015 |
| Description | RASP UK Consortium |
| Organisation | University of Leicester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers. |
| Collaborator Contribution | The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED. The RASP-UK legacy Committee has been established to ensure that all data and samples from the RASP-UK programme will continue to serve a scientifically and ethically just purpose, including managing requests from external sources outside of the RASP-UK programme for the use of the RASP-UK trial data and/or samples stored for future ethically approved research. The clinical and omics data sets of RASP-UK have been successfully uploaded to the tranSMART platform, which platform enables real-time analyses. It has been aligned with the UBIOPRED and SOMOSA datasets and ensures accessibility, sustainability and transparency of data which is essential for future respiratory projects within the EU and the UK. Requests for accessing the RASP-UK data management platform will be managed by the RASP-UK Legacy Committee. |
| Impact | Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015 |
| Start Year | 2015 |
| Description | RASP UK Consortium |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers. |
| Collaborator Contribution | The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED. The RASP-UK legacy Committee has been established to ensure that all data and samples from the RASP-UK programme will continue to serve a scientifically and ethically just purpose, including managing requests from external sources outside of the RASP-UK programme for the use of the RASP-UK trial data and/or samples stored for future ethically approved research. The clinical and omics data sets of RASP-UK have been successfully uploaded to the tranSMART platform, which platform enables real-time analyses. It has been aligned with the UBIOPRED and SOMOSA datasets and ensures accessibility, sustainability and transparency of data which is essential for future respiratory projects within the EU and the UK. Requests for accessing the RASP-UK data management platform will be managed by the RASP-UK Legacy Committee. |
| Impact | Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015 |
| Start Year | 2015 |
| Description | RASP UK Consortium |
| Organisation | University of Nottingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers. |
| Collaborator Contribution | The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED. The RASP-UK legacy Committee has been established to ensure that all data and samples from the RASP-UK programme will continue to serve a scientifically and ethically just purpose, including managing requests from external sources outside of the RASP-UK programme for the use of the RASP-UK trial data and/or samples stored for future ethically approved research. The clinical and omics data sets of RASP-UK have been successfully uploaded to the tranSMART platform, which platform enables real-time analyses. It has been aligned with the UBIOPRED and SOMOSA datasets and ensures accessibility, sustainability and transparency of data which is essential for future respiratory projects within the EU and the UK. Requests for accessing the RASP-UK data management platform will be managed by the RASP-UK Legacy Committee. |
| Impact | Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015 |
| Start Year | 2015 |
| Description | RASP UK Consortium |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers. |
| Collaborator Contribution | The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED. The RASP-UK legacy Committee has been established to ensure that all data and samples from the RASP-UK programme will continue to serve a scientifically and ethically just purpose, including managing requests from external sources outside of the RASP-UK programme for the use of the RASP-UK trial data and/or samples stored for future ethically approved research. The clinical and omics data sets of RASP-UK have been successfully uploaded to the tranSMART platform, which platform enables real-time analyses. It has been aligned with the UBIOPRED and SOMOSA datasets and ensures accessibility, sustainability and transparency of data which is essential for future respiratory projects within the EU and the UK. Requests for accessing the RASP-UK data management platform will be managed by the RASP-UK Legacy Committee. |
| Impact | Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015 |
| Start Year | 2015 |
| Description | RASP UK Consortium |
| Organisation | University of Southampton |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers. |
| Collaborator Contribution | The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED. The RASP-UK legacy Committee has been established to ensure that all data and samples from the RASP-UK programme will continue to serve a scientifically and ethically just purpose, including managing requests from external sources outside of the RASP-UK programme for the use of the RASP-UK trial data and/or samples stored for future ethically approved research. The clinical and omics data sets of RASP-UK have been successfully uploaded to the tranSMART platform, which platform enables real-time analyses. It has been aligned with the UBIOPRED and SOMOSA datasets and ensures accessibility, sustainability and transparency of data which is essential for future respiratory projects within the EU and the UK. Requests for accessing the RASP-UK data management platform will be managed by the RASP-UK Legacy Committee. |
| Impact | Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015 |
| Start Year | 2015 |
| Description | RASP UK Consortium |
| Organisation | Vitalograph |
| Country | Global |
| Sector | Private |
| PI Contribution | Programme leader: Professor Liam Heaney (MD MRCP MB BCh BaO) The RASP-UK consortium is led by Professor Liam Heaney, a professor of Respiratory Medicine at Queens University Belfast and consultant physician at Belfast City Hospital. Professor Heaney is an advocate of a stratified approach to providing optimal care for patients with severe asthma. He founded the British Thoracic Society Difficult Asthma Network and the affiliated National Registry on Difficult Asthma in 2006. He now co-ordinates and manages the registry, which facilitates research into the assessment and clinical management of difficult asthma, standardising UK specialist clinical services. Professor Heaney's research group at Queen's University Belfast, have conducted award winning research. His team defined the significant scale of the problem of non-adherence to treatment in patients with severe asthma and the group are addressing this by developing clinical tests utilising exhaled nitric oxide suppression and biomarkers, for use in clinical assessments of non-adherence. His contribution to asthma research also spans the establishment of in vitro cell models and he has pioneered work on non-bronchoscopic sampling of paediatric airways for the advancement of studies on airway disorders in children. Professor Heaney continues to collaborate with industrial partners, concerned with profiling genomic expression for biomarkers. |
| Collaborator Contribution | The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry and Asthma UK. The Consortium works with the partner NHS Trusts of the listed Academic Institutions but additionally includes NHS partners Newcastle NHS Trust, Heart of England NHS Trust, Royal Brompton and Harefield NHS Foundation Hospital, and Greater Glasgow Health Board. The RASP UK consortium works closely with with Royal College of Surgeons in Ireland, the National Institute for Health Research Office for Clinical Research Infrastructure Respiratory TRP, British Thoracic Society, and the EU Consortia and UBIOPRED. The RASP-UK legacy Committee has been established to ensure that all data and samples from the RASP-UK programme will continue to serve a scientifically and ethically just purpose, including managing requests from external sources outside of the RASP-UK programme for the use of the RASP-UK trial data and/or samples stored for future ethically approved research. The clinical and omics data sets of RASP-UK have been successfully uploaded to the tranSMART platform, which platform enables real-time analyses. It has been aligned with the UBIOPRED and SOMOSA datasets and ensures accessibility, sustainability and transparency of data which is essential for future respiratory projects within the EU and the UK. Requests for accessing the RASP-UK data management platform will be managed by the RASP-UK Legacy Committee. |
| Impact | Publications Research in Progress -Medical Research Council Refractory Asthma Stratification Consortium, Heaney LG et al, Doi: 10.1136/thoraxjnl-2015-207326 Drug therapies in severe asthma - the era of stratified medicine, Kathy J Hetherington and LG Heaney, Clinical Medicine 2015 Vol 15, No 5: 452-6 Conference Presentations Thoracic Society of Australia and New Zealand 5th April 2016, Perth Australia - Stratified Medicine in Severe Asthma - the RASP-UK Consortium programme, Professor Liam Heaney - invited keynote speaker in session "Towards innovative solutions for severe asthma" Centre of Research Excellence Seminar Series and Webinar, Newcastle, New South Wales, Australia 8th April 2016 - Stratified Medicine in Severe Asthma, Professor Liam Heaney BTS Winter Meeting 2016 Fractional exhaled nitric oxide (FeNO)suppression to identify non-adherence in difficult asthma KJ Hetherington, RW Costello, LG Heaney EACCI Congress 2017 Biomarkers of type 2 high and type 2 low inflammation in asthma LG Heaney EACCI Congress 2017 How can we improve asthma medication adherence? Hetherington KJ Poster Presentation Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG et al; Stratified, personalised or P4 medicine' organised by the Academy of Medical Sciences, Medical Research Council, Science Europe and the University of Southampton Slide Presentation MRC - Precision Medicine UK: Collaboration Nation - Stratified Medicine in Severe Asthma UK Refractory Asthma Stratification Programme (RASP-UK), Heaney LG; Precision Medicine UK: Collaboration Nation event, Dec 2015 |
| Start Year | 2015 |
| Title | BenRex:Asthma Exacerbation Profile in patients on open label treatment with Benralizumab for severe eosinophilic asthma - an exploratory study |
| Description | The main focus of this project will be to understand the nature of asthma exacerbations that occur despite open label benralizumab therapy in severe eosinophilic asthma. In addition, the efficacy of benralizumab has been clearly demonstrated in placebo-controlled trials and now effectiveness and early predictors of response in the real world need to be considered. This pragmatic study will include people selected in a real world scenario treated with open label benralizumab injections for one year. Each exacerbation event where the patient is able to travel to the research site will be studied for the inflammatory and clinical profile and samples stored for microbiome analysis. This is a UK multicentre study in NHS Clinical Centres with a dedicated tertiary care difficult asthma service across a total of 15 sites. The study is funded by industry collaboration under Workstrand 4 of RASP UK Consortium Agreement. Consistent with our plan to try and better understand exacerbation events and potentially reduce OCS use in patients with severe asthma on biologic therapy, the BENREX study (BENREX) will finish in February 2024. There is significant interest at the minute in the concept of clinical remission in severe asthma with biologic therapy (Expert consensus framework for asthma remission as a treatment goal ) and AstraZeneca has provisionally agreed to long-term follow-up of this patient cohort to determine how many achieve clinical remission and how many maintain this over a sustained period of time (estimated to extend to 2027 - contract being finalised). This data will provide additional data on the reasons for failure to achieve remission in this well characterised cohort with precise clinical and biomarker phenotyping. Patent recruitment: 137. Study end date February 2024. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2017 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | This study was delayed substantially due to the pandemic requiring substantial protocol modification, which was utilised as an opportunity to adjust the protocol for the pandemic using digital and remote monitoring technologies (Adapting BenRex Study Design). https://erj.ersjournals.com/content/58/suppl_65/PA1108 |
| URL | https://clinicaltrials.gov/show/NCT04102800 |
| Title | Exacerbation Profile In Patients On Mepolizumab For Severe Refractory Eosinophilic Asthma - An Exploratory Study |
| Description | Background: Clinical trials with mepolizumab, a humanised monoclonal antibody against interleukin-5, show a 50% reduction in severe asthma exacerbations in people with severe eosinophilic asthma. Exacerbations in patients treated with mepolizumab seem to be different to exacerbations in those given placebo, as patients treated with mepolizumab report fewer symptoms, have a lower sputum eosinophil count, and smaller fall in peak expiratory flow. We aimed to investigate the inflammatory phenotype and physiological characteristics of exacerbation events in patients with severe eosinophilic asthma who were treated with mepolizumab. Methods: This multicentre, prospective, observational cohort study was carried out at four UK specialist severe asthma centres. Participants were aged 18-80 years, with severe eosinophilic asthma (Global Initiative for Asthma steps 4 and 5), and were eligible for mepolizumab therapy. All participants received mepolizumab 100 mg subcutaneously every 4 weeks, had a scheduled study visit when stable on mepolizumab (=3 months on treatment), and measured daily peak flow and completed symptoms diaries throughout the course of the study. Participants attended their study centre for unscheduled exacerbation assessment when symptoms worsened outside of their normal daily variation and before commencing rescue treatment. If a participant was unable to attend their study centre for exacerbation or had initiated rescue treatment before the study visit, clinical details of the missed exacerbation were collected by clinical staff. In this exploratory study, the endpoint was 100 clinical assessments at exacerbation completed across all sites for participants on mepolizumab before initiation of rescue treatment. Characteristics of those who had exacerbations on mepolizumab were compared with those who did not, peak flow and symptoms diaries were compared for assessed versus missed exacerbations, and exacerbation phenotypes defined by sputum eosinophil cell count were compared. The utility of fractional exhaled nitric oxide (FeNO) and C-reactive protein in determining exacerbation phenotype on mepolizumab treatment were also assessed. This study is registered with ClinicalTrials.gov, NCT03324230. Findings: Between Nov 30, 2017, and May 29, 2019, 145 participants were enrolled and treated with mepolizumab, five were excluded from the analysis. 172 exacerbations occurred, with 96 (56%) assessed before commencing rescue treatment. Compared with patients who did not exacerbate, patients who exacerbated had a higher exacerbation rate and more emergency department attendances in the year before commencing mepolizumab. The change in peak expiratory flow at nadir in the assessed exacerbation group was mean -40·5 L/min (SD 76·3) versus mean -37·0 L/min (93·0; p=0·84) in the missed exacerbation group, and there was no difference in reported symptom burden. When comparing exacerbations with a high sputum eosinophil count (=2%; SEHIGH) with exacerbations with a low sputum eosinophil count (<2%; SELOW), the SEHIGH exacerbations were FeNO high (median difference 33 parts per billion [ppb; 95% CI 8 to 87]; p=0·0004), with lower FEV1 percent predicted (mean difference -15·9% [-27·0 to -4·8]; p=0·0075), lower FEV1 to forced vital capacity ratio (mean difference -10·3 [-17·0 to -3·6]; p=0·0043), and higher blood eosinophil counts (median difference 40 cells per µL [20 to 70]; p=0·0009). By contrast, SELOW exacerbations had higher C-reactive protein concentrations (median difference 12·7 mg/L [3·5 to 18·5]; p<0·0001), higher sputum neutrophil counts (median difference 52·7% [34·5 to 59·2]; p<0·0001), and were more likely to be treated with antibiotics (p=0·031). FeNO (=20 or =50 ppb) was the most useful discriminator of inflammatory phenotype at exacerbation. The most common adverse event was hospital admission due to asthma exacerbation (17 [50%] of 34 events), none of the adverse events were study procedure related. Interpretation: Exacerbations on mepolizumab are two distinct entities, which can largely be differentiated using FeNO: non-eosinophilic events are driven by infection with a low FeNO and high C-reactive protein concentration, whereas eosinophilic exacerbations are FeNO high. The results of the MEX study challenge the routine use of oral corticosteroids for the treatment of all asthma exacerbation events on mepolizumab, as well as the switching of biological therapies for treatment failure without profiling the inflammatory phenotype of ongoing asthma exacerbations. The results highlight clinically available tools to enable profiling of these residual exacerbations in patients treated with mepolizumab. In a further analysis, supported by additional funding from GSK, we have performed proteomic analysis (1156 proteins measured in sputum - O link Proximity Extension Assay. Unsupervised classification identified a distinct cluster of patients with a long disease duration, characterised by persistent eosinophilic airway inflammation and a population of airway eosinophils which are not IL-5 dependent. This persistent eosinophilic inflammation was characterised by increased IL-1 and IL-6 related proteins and notably, this distinction was evident pre-Mepolizumab and was associated with significantly longer disease duration (manuscript in preparation). This intriguing finding suggests differentially regulated populations of eosinophils in the airway which may reflect a compensatory mechanism to prolonged CS exposure in severe asthma, which we are currently exploring further using our biobanked samples in MEX and the biomarker study. The results of the MEX study (MEX study) have challenged the routine use of OCS for the treatment of all asthma exacerbation events, particularly in patients on biologic therapy. Clinicians in the UK are currently using this data to better target OCS and advanced discussions are ongoing in the UK to submit a grant application across the RASP-UK centres for a controlled (prednisolone v placebo) in biomarker low subjects on biologic therapy. |
| Type | Management of Diseases and Conditions |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2017 |
| Development Status | Closed |
| Clinical Trial? | Yes |
| Impact | None yet. |
| URL | https://clinicaltrials.gov/show/NCT03324230 |
| Title | Inhaler Compliance Assessment (Asthma) INCA SUN |
| Description | Background: The clinical value of using digital tools to assess adherence and lung function in uncontrolled asthma is not known. Treatment decisions guided by digitally-acquired data on adherence, inhaler technique, and peak flow were compared with current methods. Methods: A 32-week multicenter single-blind randomized clinical trial (NCT02307669) was conducted in 10 asthma clinics across Ireland and England between October 25, 2015, and September 5, 2020. Participants were >18 years had uncontrolled asthma, and =1 exacerbation in the last year despite high dose inhaled corticosteroids. There were 3 education visits over 8-weeks, and 3 treatment adjustment visits over 24-weeks. Patients were randomized in a 1:1 ratio, using a computer-generated randomization sequence of permuted blocks of varying sizes stratified by FeNO levels. In the active group, treatment adjustments were informed by digital data on inhaler adherence and PEF. Treatment was adjusted in the control group based on pharmacy refill rates, asthma control, and risk of exacerbations. Both groups used a digitally-enabled inhaler and PEF. The primary outcomes were asthma medication burden and adherence. Results: Two hundred-twenty patients consented, 213 were randomized (control: 105) and 200 completed the study. In ITT analysis at week 32, 14 active (14%) and 31 (32%) control patients had a net increase in treatment compared to baseline, OR 0.31, 95%CI [0.15-0.64], p=0.002, 11(11%) active and 21(21%) controls required add-on biologic therapy, OR 0.42, 95%CI [0.189-0.95], p=0.038). Three of 19 (16%) active and 11 of 28 (40%) control patients were increased to 1,000mcg/day OR 0.26; 95%CI [0.07-0.99], p=0.049, 26 of 83 (31%) active and 13 of 73 (18%) controls were reduced to FP 500mcg/day, OR 2.11, 95%CI [1.01-4.74], p=0.047). Week 20-32 adherence was 55.5% (26.8%) in the control group and 64.9% (23.5%) in the active group, difference: 9.4%, 95%CI [2.31-16.4], p=0.01. Despite a lower treatment burden in the active group, there were no differences in asthma control, lung function, T2 inflammation, or exacerbations between the two groups. Interpretation: Evidence-based care informed by digital data led to a modest improvement in medication adherence and a significantly lower treatment burden. |
| Type | Therapeutic Intervention - Medical Devices |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2016 |
| Development Status | Closed |
| Clinical Trial? | Yes |
| Impact | N/A |
| URL | http://www.incadevice.com/inca-sun-study/ |
| Title | Persistence Of Inflammation And Study Of T2 Pathways Following Inhibition Of Interleukin-5 With Mepolizumab In Severe Eosinophilic Asthma - MAPLE |
| Description | Background: Mepolizumab inhibits IL-5 activity and reduces exacerbation frequency and maintenance oral corticosteroid (OCS) dosage in patients with severe eosinophilic asthma (SEA). Some patients remain dependent on OCS despite anti-IL-5 treatment, suggesting residual corticosteroid-responsive mechanisms. Objective: To determine the clinical and anti-inflammatory effects of OCS in patients with SEA on mepolizumab. Methods: We conducted a randomized, triple-blind, placebo-controlled crossover trial of prednisolone (0.5 mg/kg/d, maximum 40 mg/d, for 14 ± 2 days) in adults with SEA after 12 or more weeks of mepolizumab. We compared change in asthma symptoms, quality of life, lung function measured by spirometry and airwave oscillometry, fractional exhaled nitric oxide, and blood and sputum eosinophil cell count after prednisolone and placebo treatment. Results: A total of 27 patients completed the study. Prednisolone did not improve 5-item Asthma Control Questionnaire (mean difference in change for prednisolone vs placebo, -0.23; 95% CI, -0.58 to 0.11), mini-Asthma Quality of Life Questionnaire (0.03; 95% CI, -0.26 to 0.42), St. George's Respiratory Questionnaire (0.24; 95% CI, -3.20 to 3.69), or Visual Analogue Scale scores for overall asthma symptoms (0.11; 95% CI, -0.58 to 0.80). The mean difference for FEV1 in favor of prednisolone was 105 mL (95% CI, -4 to 213 mL); forced expiratory flow at 25% and 75% 484 mL/s (95% CI, 151 to 816 mL/s); fractional exhaled nitric oxide reduction 41% (95% CI, 25% to 54%); blood eosinophil count reduction 49% (95% CI, 31% to 62%); and percentage of sputum eosinophil reduction 71% (95% CI, 26% to 89%). Conclusions: OCS improved small-airway obstruction and reduced biomarkers of type 2 inflammation but had no significant effect on symptoms or quality of life in patients with SEA receiving treatment with mepolizumab |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2018 |
| Development Status | Closed |
| Clinical Trial? | Yes |
| Impact | None yet. |
| URL | https://clinicaltrials.gov/show/NCT03610685 |
| Title | RASP Bronchoscopy Study |
| Description | This is a multi-centre bronchoscopy study designed to investigate the underlying molecular pathways driving severe asthma. This improved mechanistic understanding is important for the identification and effective targeting of novel therapeutic targets in severe asthma. The primary endpoint is the gene expression levels in airway biopsies and brushes from corticosteroid-optimised patients with severe asthma. The study received ethical approval in July 2016. Study completed October 2019. Database lock 2020. We have published the immunohistology data from the RASP-UK bronchoscopic study (RASP-UK bronchoscopy immunohistology), which has demonstrated suppressed airway mucosal eosinophilic inflammation in both T2-high and T2-low asthma, but persistent T2 cytokine production in T2-high asthma compared to T2-low asthma. Both T2-high and T2-low asthma demonstrate persistent remodelling, namely increased airway smooth muscle mass, increased glandular mass, and increased mucus (MUC5AC) production, when compared to healthy controls. These data suggest i) that local exposure to ICS is having an impact on tissue eosinophils, which are highly sensitive to steroids, but may not suppress cells that produce T2 cytokines such as ILC2 cells and mast cells, ii) that as eosinophil-targeted biologics work most effectively in those with high T2-biomarkers, it is systemic eosinophils that drive eosinophilic asthma exacerbations rather than resident tissue eosinophils, and iii) as airway remodelling changes (increased ASM mass, glandular hyperplasia and excess mucus production) persist in both severe T2 biomarker-high and T2 biomarker-low asthma, these are responsible for residual disease expression beyond eosinophilic inflammation. Considering that bronchoconstriction and mucus plugging are predominant causes of airflow obstruction driving asthma symptoms, exacerbations and death, the factors that sustain these abnormal pathological features should be a priority for future research and drug development. The key findings to-date from the bronchoscopy study are that T2 biomarker-high CS-insensitive patients had elevated airway T2-cytokines (IL-4/-5), chemokines (CCL17/-26), alarmins (IL-33, TSLP), and eosinophils in sputum, and a high T2-dependent gene signature. T2-high patients also had a lower IL-17-dependent gene signature in keeping with previous studies. Gene Set Enrichment Analysis suggests several distinct previously unidentified pathways are up/downregulated in T2-high and T2-low asthma - this is the subject of ongoing analysis. To our surprise, we found similar eosinophil, neutrophil and mast cell tissue numbers across severe asthma and health. By contrast remodelling features (ASM mass, MUCAC expression) were increased across all asthma phenotypes, and lipid mediators (PGD2 and LTE4) were similar across the asthma groups suggesting ongoing mast cell activation. Thus airway remodelling and mast cell activation are evident in both T2-high and T2-low severe asthma, and are likely important for residual disease expression beyond eosinophilic exacerbations, and an important area for further study. |
| Type | Management of Diseases and Conditions |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2016 |
| Development Status | Closed |
| Impact | Not applicable at this stage |
| Title | RASP UK Biomarker Study |
| Description | Background Asthma treatment guidelines recommend increasing corticosteroid dose to control symptoms and reduce exacerbations. This approach is potentially flawed because symptomatic asthma can occur without corticosteroid responsive type-2 (T2)-driven eosinophilic inflammation, and inappropriately high-dose corticosteroid treatment might have little therapeutic benefit with increased risk of side-effects. We compared a biomarker strategy to adjust corticosteroid dose using a composite score of T2 biomarkers (fractional exhaled nitric oxide [FENO], blood eosinophils, and serum periostin) with a standardised symptom-risk-based algorithm (control). Methods We did a single-blind, parallel group, randomised controlled trial in adults (18-80 years of age) with severe asthma (at treatment steps 4 and 5 of the Global Initiative for Asthma) and FENO of less than 45 parts per billion at 12 specialist severe asthma centres across England, Scotland, and Northern Ireland. Patients were randomly assigned (4:1) to either the biomarker strategy group or the control group by an online electronic case-report form, in blocks of ten, stratified by asthma control and use of rescue systemic steroids in the previous year. Patients were masked to study group allocation throughout the entirety of the study. Patients attended clinic every 8 weeks, with treatment adjustment following automated treatment-group-specific algorithms: those in the biomarker strategy group received a default advisory to maintain treatment and those in the control group had their treatment adjusted according to the steps indicated by the trial algorithm. The primary outcome was the proportion of patients with corticosteroid dose reduction at week 48, in the intention-to-treat (ITT) population. Secondary outcomes were inhaled corticosteroid (ICS) dose at the end of the study; cumulative dose of ICS during the study; proportion of patients on maintenance oral corticosteroids (OCS) at study end; rate of protocol-defined severe exacerbations per patient year; time to first severe exacerbation; number of hospital admissions for asthma; changes in lung function, Asthma Control Questionnaire-7 score, Asthma Quality of Life Questionnaire score, and T2 biomarkers from baseline to week 48; and whether patients declined to progress to OCS. A secondary aim of our study was to establish the proportion of patients with severe asthma in whom T2 biomarkers remained low when corticosteroid therapy was decreased to a minimum ICS dose. This study is registered with ClinicalTrials.gov, NCT02717689 and has been completed. Findings Patients were recruited from Jan 8, 2016, to July 12, 2018. Of 549 patients assessed, 301 patients were included in the ITT population and were randomly assigned to the biomarker strategy group (n=240) or to the control group (n=61). 28·4% of patients in the biomarker strategy group were on a lower corticosteroid dose at week 48 compared with 18·5% of patients in the control group (adjusted odds ratio [aOR] 1·71 [95% CI 0·80-3·63]; p=0·17). In the per-protocol (PP) population (n=121), a significantly greater proportion of patients were on a lower corticosteroid dose at week 48 in the biomarker strategy group (30·7% of patients) compared with the control group (5·0% of patients; aOR 11·48 [95% CI 1·35-97·83]; p=0·026). Patient choice to not follow treatment advice was the principle reason for loss to PP analysis. There was no difference in secondary outcomes between study groups and no loss of asthma control among patients in the biomarker strategy group who reduced their corticosteroid dose. Interpretation Biomarker-based corticosteroid adjustment did not result in a greater proportion of patients reducing corticosteroid dose versus control. Understanding the reasons for patients not following treatment advice in both treatment strategies is an important area for future research. The prevalence of T2 biomarker-low severe asthma was low. |
| Type | Management of Diseases and Conditions |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2015 |
| Development Status | Closed |
| Clinical Trial? | Yes |
| Impact | Not applicable yet. |
| URL | http://www.rasp.org.uk |
| Title | Service Evaluation of FeNO suppression test in severe asthma clinics |
| Description | Biomarker based assessment of adherence with inhaled steroids (FeNO suppression test) Non-adherence with inhaled corticosteroids (ICS) in poorly controlled severe asthma is common and consistently associated with poor clinical outcome. Adherence intervention studies using monitoring technologies and behavioural interventions have yielded mixed results but most studies have not aligned interventions with "biomarker based" assessment of therapeutic response to interpret clinical outcome. Poor adherence is a major stumbling block to improving asthma control and the development and validation of readily available protocol-driven adherence assessments would minimise the risk of committing patients with severe disease to inappropriate long-term expensive biological treatment. A number of novel biologic therapies targeting the Type-2 cytokine axis have shown efficacy in patients with severe asthma and payer organisations (e.g. the National Institute for Health and Care Excellence in the UK) provide guidance on access to these treatments. They are recommended as add-on therapies to optimised standard treatment including high dose ICS along with other controller medication, but no guidance is given on how to determine optimised standard therapy or adherence. Assessment of adherence to inhaled treatments can be challenging and physician estimate and patient self-report consistently overestimate adherence when compared to objective measures and other surrogate measures such as prescription records have limitations. Monitoring technologies remain the gold standard in clinical trials but clinical services have been slow to embrace these as part of routine care. We need to move away from trying to use challenging and imperfect surrogate measures of adherence to measuring the response to ICS using a responsive biomarker (fractional exhaled nitric oxide - FeNO). In patients with difficult to control severe asthma, this approach (FeNO suppression test) has previously been shown to identify "clinical non-adherence" when used with directly observed treatment over a seven day period. RASP-UK has now demonstrated that the FeNO suppression test can be delivered in routine clinical care and is straightforward to use for both the patient and the clinician. Profiling the FeNO response to ICS in patients with difficult to control severe asthma identifies a substantial population of patients who derive important clinical benefits from monitored ICS/LABA treatment. This approach also assists patients who wish to engage with a monitoring strategy in routine care and identifies patients who despite good adherence with inhaled treatment are likely to require additional treatment. Profiling the FeNO response to ICS exposure in patients with difficult to control severe asthma is a helpful part of clinical phenotyping and can usefully identify those who are likely to respond well to standard care with optimised treatment. In addition, aligning monitoring of ICS treatment with FeNO response will help exclude ICS responsive non-adherent subjects prior to recruitment to clinical trials investigating "add-on" interventions to standard care. This approach will also facilitate mechanistic studies investigating true ICS resistant disease. Future studies are required to identify the optimal intervention to maintain ongoing adherence in a difficult to control severe asthma population, but understanding the potential therapeutic benefit in an individual patient is an important component of routine assessment and clinical decision making. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2017 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | Manuscript under review. |
| URL | https://clinicaltrials.gov/show/NCT01219036 |
| Title | Somosa Study |
| Description | Importance: The monoclonal biologic omalizumab targets IgE, a key asthma mediator, but there are no tests to predict its clinical efficacy. Objective: To identify biomarkers that predict clinical improvement during one year of omalizumab treatment. Design: 1-year, open-label, Study of Mechanisms of action of Omalizumab in Severe Asthma (SoMOSA), in two phases: 0-16 weeks, to assess early clinical improvement by Global Evaluation of Therapeutic Effectiveness (GETE), and 16-52 weeks, assessing late responses, i.e. =50% decrease in asthma exacerbations or dose of maintenance oral corticosteroids (mOCS). Setting: Multicenter, involving 17 tertiary referral clinics for severe asthma. Participants: Severe asthma (GINA step 4/5) uncontrolled (ACQ=1.5, atopic, frequent daytime symptoms or night-time awakening, =2 severe exacerbations in the past year) despite high-dose inhaled corticosteroids and long-acting ß-agonists, requiring or not mOCS for disease control. Interventions: All participants received omalizumab as standard-of-care and provided samples (exhaled breath, blood, induced sputum and urine) before and after 16 and 52 weeks of treatment. Main outcomes and Measurements: The main outcome was the effect of omalizumab treatment on urinary levels of prostaglandin D2 metabolite, 2, 3-dinor-11-ß-PGF2a, omics biomarkers and standard clinical biomarkers, exhaled nitric oxide, blood and sputum eosinophils and serum IgE. We report here the key secondary objective, i.e. biomarkers predictive of early/late clinical responses, as judged by random forest analysis of randomised training and test sets of biomarker data collected before starting treatment. Results: Of 216 patients enrolled, 191 completed the first and 173 the second phase: 63% of 191 had early improvement, in 69% (120/173) exacerbations were reduced by =50% and 57% (37/65) of patients on mOCS reduced their dose by =50% by 52 weeks. Five breathomics (GC-MS) and 5 plasma lipid biomarkers strongly predicted (receiver operating characteristic area under the curve: 0.835 and 0.949, respectively) the reduction in exacerbation rates, a key clinical outcome for severe asthma, while the 2, 3-dinor-11-ß-PGF2a, or standard clinical biomarkers did not (ROC<0.7). Conclusions and Relevance: This is the first identification of omics biomarkers that can predict improvement to a biologic for severe asthma, justifying their further prospective validation and development. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2015 |
| Development Status | Closed |
| Clinical Trial? | Yes |
| Impact | N/A at this stage |
| URL | http://www.southampton.ac.uk/ctu/trialportfolio/listoftrials/somosa |
| Description | Asthma UK Press Release |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Inform stakeholders about the MRC funding announcement, the RASP UK research and potential impact for asthma patients. |
| Year(s) Of Engagement Activity | 2015 |
| URL | https://www.asthma.org.uk/about/media/news/medical-research-council-mrc-asthma-uk-and-leading-pharma... |
| Description | BTS 2017 Winter Meeting Presentation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Update in Asthma Treatment: Personalised Medicine Slide Presentation at the annual British Thoracic Society Winter Meeting December 2017 |
| Year(s) Of Engagement Activity | 2017 |
| Description | European Forum for Education in Allergy and Airways Disease September 2021 and September 2022 Masterclass Invited Speaker |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Heaney as Academic Lead disseminating the RASP-UK programme outputs and impacts. |
| Year(s) Of Engagement Activity | 2021,2022 |
| URL | https://www.euforea.eu/events/update-biologicals-severe-asthma |
| Description | European Respiratory Society Satellite Symposium keynote speaker March 2021 and March 2023 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Heaney as Academic Lead disseminating the RASP-UK programme outputs and impacts. |
| Year(s) Of Engagement Activity | 2021,2023 |
| URL | https://channel.ersnet.org/media-292-ers-satellites-2023-2-march-2023 |
| Description | Global Respiratory Leadership Forum |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | 'Personalised dosing of inhaled steroids' presented to Global Respiratory Leadership Forum, Gothenburg, Sweden, 5th - 6th April 2019 Dr Garrett Greene |
| Year(s) Of Engagement Activity | 2019 |
| Description | Hong Kong Institute of Allergy June 2021 Invited Speaker |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Heaney as Academic Lead disseminating the RASP-UK programme outputs and impacts. |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://www.allergy.org.hk/hkac2021.html |
| Description | ISAF 2018 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Lecture entitled Different Endotypes and Phenotypes drive the Heterogeneity in Severe Asthma presented to the International Severe Asthma. Forum Madrid, November 2018. |
| Year(s) Of Engagement Activity | 2018 |
| Description | India Severe Asthma Expert Forum May 2021 Invited Speaker |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Heaney as Academic Lead disseminating the RASP-UK programme outputs and impacts. |
| Year(s) Of Engagement Activity | 2021 |
| Description | Invited Speaker Hong Kong Thoracic Society March 2021 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Heaney as Academic Lead disseminating the RASP-UK programme outputs and impacts. |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://hkts.hk/index/meetings/hkts-chest-meetings/annual-scientific-meetings?detail=1&aid=1512 |
| Description | Meet the Expert Severe Asthma Japan March 2022 Invited Speaker |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Heaney as Academic Lead disseminating the RASP-UK programme outputs and impacts. |
| Year(s) Of Engagement Activity | 2022 |
| Description | NICHE Email Campaign |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | NICHE email campaign circulating news stories, press releases and articles to approx 16,000 people. |
| Year(s) Of Engagement Activity | 2015,2016,2017 |
| Description | Portuguese National Respiratory Congress November 2021 Invited Speaker |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Heaney as Academic Lead disseminating the RASP-UK programme outputs and impacts. |
| Year(s) Of Engagement Activity | 2021 |
| Description | RASP UK Newsletter |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Newsletter to regularly update study team members and professional practitioners on the progress of the study and invite articles from consortium members. Disseminates information to consortium members, industry bodies, patient input platform representatives and funding bodies. |
| Year(s) Of Engagement Activity | 2015,2016,2017 |
| URL | http://www.rasp.org.uk |
| Description | RASP UK Twitter RASP-UK @Br3ath3_deep |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Twitter Feed |
| Year(s) Of Engagement Activity | 2016,2017,2018,2019,2020,2021 |
| URL | https://twitter.com/Br3ath3_Deep |
| Description | RASP UK Website |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | The website is one element of the dissemination and exploitation plan being used to direct project finding dissemination and build project awareness in anticipation of the reporting phase of the project maximizing its clinical exploitation potential. Its objective is to lay down the foundations for effective external communication of RASP-UK's concept and potential benefits to interested stakeholders at an international level, focusing primarily in the UK and Europe. The project will continue to take advantage of Asthma UK's media and press function, as well as its communication channels which reach many thousands of people with asthma. |
| Year(s) Of Engagement Activity | 2015,2016,2017 |
| URL | http://www.rasp.org.uk |
| Description | Severe Asthma Expert Summit Switzerland Cotober 2021 Invited Speaker |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Heaney as Academic Lead disseminating the RASP-UK programme outputs and impacts. |
| Year(s) Of Engagement Activity | 2021 |
| Description | Stratified Medicine in Severe Asthma RASP UK Presentation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Slide presentation delivered by Professor Liam Heaney at Precision Medicine UK Collaboration Nation event. Leading figures in the research, development and commercialisation of precision medicine in the UK gathered at an event designed to encourage new partnerships and highlight new opportunities in the field. The Precision Medicine UK: Collaboration Nation event at De Vere Holborn Bars, London, was organised by Innovate UK, Health and Care Research Wales, National Institute for Health Research, Cancer Research UK, Medical Research Council, Invest Northern Ireland and the Knowledge Transfer Network. It was part of a programme to make the UK a world leader in the field. |
| Year(s) Of Engagement Activity | 2015 |
| URL | https://www.gov.uk/government/news/precision-medicine-uk-leaders-gather-to-discuss-new-treatments |
| Description | Thoracic Society of Australia Keynote |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Keynote Speaker at Thoracic Society of Australia and New Zealand: Stratified Medicine in Severe Asthma - the RASP UK Consortium Programme 5th April 2016 |
| Year(s) Of Engagement Activity | 2016 |
| Description | VI International Symposium on Immunotherapy and Biologics, Mexico (November 2021) Invited Speaker |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Heaney as Academic Lead disseminating the RASP-UK programme outputs and impacts. |
| Year(s) Of Engagement Activity | 2021 |
| Description | What's new in Respiratory Medicine, Greece (September 2022) Invited Speaker |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Heaney as Academic Lead disseminating the RASP-UK programme outputs and impacts. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.conferre.gr/event-detail.aspx?event=572 |
| Description | Will Smart Inhalers Fix Adherence |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation at the ERS Satellite Symposium 20/21 February 2020 Session: Prevention of exacerbations and oral steroid use in Asthma |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.ersnet.org/congress-and-events/ers-satellite |
| Description | World Asthma Day News Item |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Update on programme delivery and raise awareness of RASP UK whilst highlighting World Asthma Day. Also promoted on LinkedIn. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://fyi-news.co.uk/rasp-uk-world-asthma-day-2016 |
| Description | iMeet the expert severe asthma Singapore June 2022 Invited Speaker |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Heaney as Academic Lead disseminating the RASP-UK programme outputs and impacts. |
| Year(s) Of Engagement Activity | 2022 |